1 APPENDICES

Appendix 1: Scope for the development of the clinical guideline ...............2
Appendix 2: Declarations of interests by GDG members .........................9
Appendix 3: Special advisors to the Guideline Development Group ..........16
Appendix 4: Stakeholders who responded to early requests for evidence .................................................................17
Appendix 6: Researchers contacted to request information about unpublished or soon-to-be published studies .........................19
Appendix 7: Analytic framework and clinical questions .........................20
Appendix 8: Review protocols ..........................................................25
Appendix 9: Search strategies for the identification of clinical studies .........................................................................................48
Appendix 10: Quality checklists for clinical studies and reviews ..............62
Appendix 11: Search strategies for the identification of health economics evidence .................................................................65
Appendix 12: Methodology checklist for economic studies ....................77
Appendix 13: Research Recommendations ........................................79

Appendix 14: Clinical evidence – study characteristics tables .............. On CD
Appendix 15: Clinical evidence – forest plots ........................................ On CD
Appendix 16: Clinical evidence – completed methodology checklists .... On CD
Appendix 17: Economic evidence – completed methodology checklists .... On CD
Appendix 18: Economic evidence – evidence tables of published studies .. On CD
Appendix 19: GRADE evidence profiles ............................................. On CD
APPENDIX 1: SCOPE FOR THE DEVELOPMENT OF THE CLINICAL GUIDELINE

Final version

1 Guideline title
Autistic spectrum conditions: diagnosis and management of autistic spectrum conditions in adults

Short title
Autistic spectrum conditions in adults

2 The remit
The Department of Health has asked NICE: ‘To produce a clinical guideline on the management of autistic spectrum disorders in adults’.

3 Clinical need for the guideline

Epidemiology
Autistic spectrum conditions are lifelong neurological conditions. The way that they are expressed in individual people will differ at different stages of their lives, in response to interventions, and if they have coexisting conditions such as learning or language difficulties. A recent study conducted by Leicester University shows that the prevalence for all autistic spectrum conditions in adults in England is approximately 1%. In the past 30 years there has been a 25-fold increase in the prevalence of autistic spectrum conditions. This is probably a result of widening diagnostic categories, including the relatively recent subgroup of Asperger’s syndrome, and the growth of services, better awareness, and improved detection. This increase has had a significant impact on referrals to diagnostic services. People with autistic spectrum conditions commonly experience difficulty with cognitive and behavioural flexibility, altered sensory sensitivity (which can have both advantages and disadvantages), sensory processing difficulties, stereotyped mannerisms, emotional regulation difficulties, and a narrow and often highly focused range of interests and activities. These features may be along a continuum from mild to severe. For a diagnosis of autistic spectrum conditions to be made there must be both the presence of impairments (as defined by the World Health Organization) and an impact on the person’s functioning.

The two major diagnostic classification systems (DSM-IV and ICD-10) use similar but not identical criteria to diagnose autistic spectrum conditions. In

---

1 We are using the term 'autistic spectrum conditions' rather than 'autistic spectrum disorders' because this is the terminology more recently used in the Department of Health’s Autism Strategy, and is preferred by many (but not all) adults on the autistic spectrum.
the guideline we use ICD-10. Where we have included disorders not clearly specified in ICD-10 we have used the relevant DSM-IV criteria.

Both DSM-IV and ICD-10 use the term pervasive developmental disorder, which encompasses autism, Asperger’s syndrome and atypical autism (or pervasive developmental disorder not otherwise specified). For the purposes of this clinical guideline the term autistic spectrum conditions is used instead of pervasive developmental disorder because it is more widely understood.

The June 2009 National Audit Office report 'Supporting people with autism through adulthood' reported that a significant proportion of adults with autism across the whole autistic spectrum are excluded both socially and economically. Their conditions are often overlooked by health, education and social care professionals, which creates barriers to accessing the support and services they need to live independently. In addition, people with autistic spectrum conditions are more likely to have coexisting mental health and medical health problems, other developmental conditions and adaptive impairments. ‘Diagnostic overshadowing’ means there may be a tendency to overlook symptoms of autistic spectrum conditions in these groups and attribute them to being part of an intellectual disability. While this is an important issue, the signs and symptoms of autism can also lead to the misdiagnosis of co-occurring disorders.

Current practice
There is wide variation in rates of identification and referral for diagnostic assessment, waiting times for diagnosis, models of multi-professional working, assessment criteria, diagnostic practice, biomedical investigation and genetic counselling for adults with features of autistic spectrum conditions. These factors contribute to delays in reaching a diagnosis and subsequent access to appropriate services.

When the diagnostic assessment process works well, professionals and carers communicate right from the start and the adults with autism are involved in the decisions relating to their care. This lays the foundation for a long-term understanding between adults with autism, carers and the professionals supporting their needs. However, many adults or their carers who suspect they have an autistic spectrum condition have had difficulties accessing a diagnostic assessment, particularly if they are not in contact with a specialist service for the assessment or treatment of another disorder. Even if they have managed to obtain a diagnosis they may receive no follow-up support because of the absence of appropriate services or of an agreed care pathway.

The use of biomedical investigations to rule out other conditions, and thresholds for referral for genetic counselling vary markedly. Opinion also varies on the value of biomedical investigations in the diagnostic assessment of autistic and coexisting conditions.
People with other existing conditions featuring intellectual, physical or sensory disability and/or mental health problems may not be recognised as having symptoms of an autistic spectrum condition. Some adults may be misdiagnosed as having personality disorders, eating disorders, or depression and their autistic spectrum condition may be overlooked.

Some of the behaviours that define autistic spectrum conditions may also feature in other disabilities (such as learning disabilities), or be the result of other conditions (such as epilepsy). People may be wrongly diagnosed as having a mental illness when they have features of an autistic spectrum condition, or they may be misdiagnosed with autism when they have another condition. Misdiagnosis can lead to delays in receiving the necessary care and support.

The process and content of information-sharing varies widely, for instance in the provision of information and support for the person and their family while awaiting diagnosis and immediately after.

Current awareness and understanding of autism in adults among front-line health, education and social care professionals leaves room for improvement. In line with the Department of Health's Autism Strategy, a better understanding of the condition may enable better service delivery.

Current treatment and management for autistic spectrum conditions is often focused on children and adolescence. Transition from child and adolescent mental health services to adult services can often be challenging and requires significant collaboration between several government organisations. Due to the qualitative impairments in communication and social interaction skills, adults with autistic spectrum conditions often have difficulty in engaging in long-term employment or other purposeful/meaningful activity, especially if the person has a learning disability.

There are variations in practice of diagnosis and appropriate referral for adults with autistic spectrum conditions. Adults at the higher end of the autistic spectrum often may not get a diagnosis because of beliefs that, for example, if a person is in a settled relationship or can talk fluently they cannot have an autistic spectrum condition. This may lead to inappropriate crisis admissions to services as a result of mental health problems, physical illness, homelessness or coming into contact with the criminal justice system. People with autistic spectrum conditions are at risk of exclusion and inequalities in service provision, particularly people from black or minority ethnic groups, older people, women and people with gender identity problems.
The Department of Health published 'Fulfilling and rewarding lives: the strategy for adults with autism in England' (2009) on designing services to improve care and support from all public services. The National Audit Office is currently undertaking a study, ‘Supporting people with autism through adulthood’, focusing particularly on the transition from adolescence to adulthood.

Clinical guidance for diagnosis has been published for the NHS in Scotland: ‘Assessment, diagnosis and clinical interventions for children and young people with autism spectrum disorders’ (Scottish Intercollegiate Guidelines Network 2007). The Autistic Spectrum Disorder Strategic Action Plan for Wales (2008) focused on the role of strategic health plans to develop services and interagency cooperation between health and education for children and young people with autistic spectrum conditions. The Autistic Spectrum Disorder (ASD) Strategic Action Plan for Wales (2009) focused on diagnosis, access to services, community support, employment and housing. This NICE guideline, along with the NICE guideline on autistic spectrum disorders in children and young people that is currently in development, will provide guidance for the NHS in England.

4 The guideline
The guideline development process is described in detail on the NICE website (see section 6, ‘Further information’).

This scope defines what the guideline will (and will not) examine, and what the guideline developers will consider. The scope is based on the referral from the Department of Health.

The areas that will be addressed by the guideline are described in the following sections.

4.1 Population
Groups that will be covered
a) Adults (18 or older), with suspected or diagnosed high functioning (for example, above average cognitive functioning) or low functioning (for example, profound communication problems) autistic spectrum conditions.

b) People with autistic spectrum conditions across the range of diagnostic groups, including atypical autism, Asperger's syndrome, pervasive developmental disorder and Rett’s syndrome.

c) Consideration will be given to the specific needs of:
people with coexisting conditions (such as dyslexia, dyspraxia, sensory sensitivity, depression, ADHD, OCD, personality disorders, eating disorders and anxiety disorders)

- women
- older people
- people from black or minority ethnic groups
- transgender people.

Groups that will not be covered
a) Children from birth up to 18 years old.

4.2 Healthcare setting
a) Primary, secondary, tertiary, health and social care and healthcare settings (including prisons and forensic services).

b) Other settings in which NHS services are funded or provided, or where NHS professionals are working in multi-agency teams.

c) The guideline will also comment on and include recommendations about the interface with other services, such as social services, education services and the voluntary sector.

4.3 Clinical management

Key clinical issues that will be covered
a) Signs and symptoms that should prompt health, education and social care professionals working with adults and/or their carers to consider the presence of an autistic spectrum condition. These will include signs and symptoms that should trigger referral for specialist assessment.

b) Validity, specificity and reliability of the components of diagnostic assessment after referral, including:
   - structure for assessment, including strengths and skills
   - diagnostic thresholds
   - assessment tools, including imaging, genetic and biomedical techniques
   - assessment of risk
   - the impact of coexisting developmental, mental and physical conditions on the assessment.

c) Psychosocial interventions, including: applied behavioural analysis, cognitive behavioural therapies, social groups, befriending schemes, mentoring and supported employment programmes.

d) Pharmacological interventions, including: anticonvulsants, antidepressants, and antipsychotics for the treatment of symptoms that may arise from coexisting conditions.
e) Physical interventions, such as diet.

f) Information and day-to-day support (such as a telephone helpline or advocates) for adults with a suspected autistic spectrum condition, and their families and carers, during the process of referral, assessment, diagnosis and the delivery of any interventions.

g) The organisation and delivery of care, and care pathways for the components of treatment and management (including transition planning), based on an ethos of multi-professional working.

Clinical issues that will not be covered

a) Coexisting conditions if an autistic spectrum condition is not a primary diagnosis.

4.4 Main outcomes

a) Diagnostic accuracy and the identification of coexisting conditions.

b) Health-related quality of life.

c) Functioning in social/occupational/educational settings.

d) Outcomes for coexisting conditions, such as depression, anxiety and substance misuse.

e) Continuity of care.

4.5 Economic aspects

Developers will take into account both clinical and cost effectiveness when making recommendations involving a choice between alternative interventions. A review of the economic evidence will be conducted and analyses will be carried out as appropriate. The preferred unit of effectiveness is the quality-adjusted life year (QALY), but a different unit of effectiveness may be used depending on the availability of appropriate clinical and utility data for adults with autistic spectrum conditions. Costs considered will be from an NHS and personal social services (PSS) perspective in the main analyses. In addition, further analyses may be conducted that will consider wider social costs associated with the care of adults with autistic spectrum conditions. Such costs may include for example special education and training costs, voluntary sector respite care costs and costs of housing services. Further detail on the methods can be found in 'The guidelines manual' (see 'Further information').

4.6 Status

Scope

This is the final scope.
Timing
The development of the guideline recommendations will begin in July 2010.

5 Related NICE guidance

Guidance under development
NICE is currently developing the following related guidance (details available from the NICE website):


6 Further information
Information on the guideline development process is provided in:

- ‘How NICE clinical guidelines are developed: an overview for stakeholders the public and the NHS’
- ‘The guidelines manual’.
- These are available from the NICE website (www.nice.org.uk/GuidelinesManual). Information on the progress of the guideline will also be available from the NICE website (www.nice.org.uk).
APPENDIX 2: DECLARATIONS OF INTERESTS BY GDG MEMBERS

With a range of practical experience relevant to autism in the GDG, members were appointed because of their understanding and expertise in healthcare for people with autism and support for their families/carers, including: scientific issues; health research; the delivery and receipt of healthcare, along with the work of the healthcare industry; and the role of professional organisations and organisations for people with autism and their families/carers.

To minimise and manage any potential conflicts of interest, and to avoid any public concern that commercial or other financial interests have affected the work of the GDG and influenced guidance, members of the GDG must declare as a matter of public record any interests held by themselves or their families which fall under specified categories (see below). These categories include any relationships they have with the healthcare industries, professional organisations and organisations for people with autism and their families/carers.

Individuals invited to join the GDG were asked to declare their interests before being appointed. To allow the management of any potential conflicts of interest that might arise during the development of the guideline, GDG members were also asked to declare their interests at each GDG meeting throughout the guideline development process. The interests of all the members of the GDG are listed below, including interests declared prior to appointment and during the guideline development process.

Categories of interest

Paid employment

Personal pecuniary interest: financial payments or other benefits from either the manufacturer or the owner of the product or service under consideration in this guideline, or the industry or sector from which the product or service comes. This includes holding a directorship, or other paid position; carrying out consultancy or fee paid work; having shareholdings or other beneficial interests; receiving expenses and hospitality over and above what would be reasonably expected to attend meetings and conferences.

Personal family interest: financial payments or other benefits from the healthcare industry that were received by a member of your family.

Non-personal pecuniary interest: financial payments or other benefits received by the GDG member’s organisation or department, but where the GDG member has not personally received payment, including fellowships.
and other support provided by the healthcare industry. This includes a grant or fellowship or other payment to sponsor a post, or contribute to the running costs of the department; commissioning of research or other work; contracts with, or grants from, NICE.

**Personal non-pecuniary interest:** these include, but are not limited to, clear opinions or public statements you have made about individuals with psychosis and substance misuse problems, holding office in a professional organisation or advocacy group with a direct interest in psychosis and substance misuse, other reputational risks relevant to psychosis and substance misuse.

### Guideline Development Group - Declarations of interest

#### Professor Simon Baron Cohen (chair)

<table>
<thead>
<tr>
<th>Employment</th>
<th>Director, Autism Research Centre, Cambridge University</th>
</tr>
</thead>
<tbody>
<tr>
<td>Personal pecuniary interest</td>
<td>Have NHS funding for an Asperger’s clinic.</td>
</tr>
<tr>
<td>Personal family interest</td>
<td>None</td>
</tr>
<tr>
<td>Non-personal pecuniary interest</td>
<td>None</td>
</tr>
<tr>
<td>Personal non-pecuniary interest</td>
<td>None</td>
</tr>
<tr>
<td>Non-personal non-pecuniary interest</td>
<td>None</td>
</tr>
<tr>
<td>Non-personal non-pecuniary interest</td>
<td>Cambridge University are conducting a trial on Oxytocin. Conduct medico-legal assessments in relation to autism.</td>
</tr>
<tr>
<td>Action Taken</td>
<td>None</td>
</tr>
</tbody>
</table>

#### Professor Gillian Baird

<table>
<thead>
<tr>
<th>Employment</th>
<th>Consultant Paediatrician and Professor of Paediatric Neurodisability. Guy’s and St Thomas’ NHS Foundation trust and King’s Health partners</th>
</tr>
</thead>
<tbody>
<tr>
<td>Personal pecuniary interest</td>
<td>None</td>
</tr>
<tr>
<td>Personal family interest</td>
<td>None</td>
</tr>
<tr>
<td>Non-personal pecuniary interest</td>
<td>None</td>
</tr>
</tbody>
</table>
| Personal non-pecuniary interest | Chair of NICE children’s & young people’s autism guideline  
Member of DSM V working party  
Member of ICD 11 working party  
Author or co-author of several papers relevant to recognition, diagnosis, coexisting conditions and management of children and young people with autism |
| Action Taken | None |

#### Dr Carole Buckley

<table>
<thead>
<tr>
<th>Employment</th>
<th>General Practitioner</th>
</tr>
</thead>
<tbody>
<tr>
<td>Personal pecuniary interest</td>
<td>None</td>
</tr>
<tr>
<td>Personal family interest</td>
<td>None</td>
</tr>
<tr>
<td>Non-personal pecuniary interest</td>
<td>None</td>
</tr>
<tr>
<td>Personal non-pecuniary interest</td>
<td>None</td>
</tr>
<tr>
<td>Action Taken</td>
<td>None</td>
</tr>
<tr>
<td>--------------</td>
<td>------</td>
</tr>
</tbody>
</table>

**Dr Peter Carpenter**

**Employment**
Consultant Psychiatrist (Learning Disabilities), Associate Medical Lead Learning Disabilities and Specialist Adult Services Avon & Wiltshire Mental Health Partnership NHS Trust

**Personal pecuniary interest**
I have been employed by the National Autistic Society as a clinican, also at present receive payments for clinical work some of which includes work in autism from Priory Healthcare and Castlebeck Com. Also receive payments for medico-legal reports relating to people with ASC.

**Personal family interest**
None

**Non-personal pecuniary interest**
Received payment from a drug company for participating in a conference.

**Personal non-pecuniary interest**
None

**Action Taken**
None

**Dr Juli Crocombe**

**Employment**
Consultant Psychiatrist, St George’s Hospital, Stafford

**Personal pecuniary interest**
None

**Personal family interest**
None

**Non-personal pecuniary interest**
Received payment from a drug company for participating in a CPD event.

**Personal non-pecuniary interest**
I support the National Autistic Society in it’s quest for the provision of appropriate and adequate health and social services for adults with Autistic Spectrum Disorder in the UK.

**Action Taken**
None

**Ms Jackie Dziewanowska**

**Employment**
Autism Spectrum Disorder Nurse Consultant Clinical Lead, Nottingham City Asperger Service

**Personal pecuniary interest**
None

**Personal family interest**
None

**Non-personal pecuniary interest**
None

**Personal non-pecuniary interest**
None

**Action Taken**
None

**Dr Marga Hogenboom**

**Employment**
General Practitioner, Camphill Medical Practice, Aberdeen.

**Medical adviser, local Camphill places in Aberdeen**

**Personal pecuniary interest**
None

**Personal family interest**
None

**Non-personal pecuniary interest**
None

**Personal non-pecuniary interest**
Director, Camphill Wellbeing Trust

**Action Taken**
None
<table>
<thead>
<tr>
<th><strong>Professor Patricia Howlin</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Employment</strong></td>
<td>Professor of Clinical Child Psychology, King’s College London and Consultant Clinical Psychologist</td>
</tr>
<tr>
<td><strong>Personal pecuniary interest</strong></td>
<td>Expert advisor/paid consultant to Dr Rick Solomons NIH funded PLAY project and paid consultant to the Rand Corporation Review of Evidence of Psychosocial and Related Interventions for Children with Autism</td>
</tr>
<tr>
<td><strong>Personal family interest</strong></td>
<td>None</td>
</tr>
<tr>
<td><strong>Non-personal pecuniary interest</strong></td>
<td>Consultation to NHS services in Cornwall and Mid Glamorgan and to the University of Oslo for which my Trust is paid</td>
</tr>
<tr>
<td><strong>Personal non-pecuniary interest</strong></td>
<td>Co-chair of the Scientific and Advisory committee of Research Autism; chair of Scientific Advisory Group, Autistica &amp; chair of MHRN Autism Clinical research group</td>
</tr>
<tr>
<td><strong>Action Taken</strong></td>
<td>Professor of Clinical Child Psychology, King’s College London and Consultant Clinical Psychologist</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Ms Annie Jones</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Employment</strong></td>
<td>Autism Specialist Nurse, Cheshire &amp; Wirral Partnership NHS Foundation Trust, Learning Disabilities Clinical Service Unit.</td>
</tr>
<tr>
<td><strong>Personal pecuniary interest</strong></td>
<td>None</td>
</tr>
<tr>
<td><strong>Personal family interest</strong></td>
<td>None</td>
</tr>
<tr>
<td><strong>Non-personal pecuniary interest</strong></td>
<td>None</td>
</tr>
<tr>
<td><strong>Personal non-pecuniary interest</strong></td>
<td>None</td>
</tr>
<tr>
<td><strong>Action Taken</strong></td>
<td>None</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Mr Campbell Main</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Employment</strong></td>
<td>Representing service user and carer concerns</td>
</tr>
<tr>
<td><strong>Personal pecuniary interest</strong></td>
<td>None</td>
</tr>
<tr>
<td><strong>Personal family interest</strong></td>
<td>None</td>
</tr>
<tr>
<td><strong>Non-personal pecuniary interest</strong></td>
<td>None</td>
</tr>
<tr>
<td><strong>Personal non-pecuniary interest</strong></td>
<td>None</td>
</tr>
<tr>
<td><strong>Action Taken</strong></td>
<td>None</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Ms Melissa McAuliffe</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Employment</strong></td>
<td>Asperger Specialist – Social Care, Rehabilitation &amp; Recovery Team</td>
</tr>
<tr>
<td><strong>Personal pecuniary interest</strong></td>
<td>None</td>
</tr>
<tr>
<td><strong>Personal family interest</strong></td>
<td>None</td>
</tr>
<tr>
<td><strong>Non-personal pecuniary interest</strong></td>
<td>None</td>
</tr>
<tr>
<td><strong>Personal non-pecuniary interest</strong></td>
<td>I am employed by LB Newham and seconded to the East London NHS Foundation Trust to work in the Asperger Service. The NICE guidelines will have a direct impact on how this service runs. I am a member of the British Association of Social Workers.</td>
</tr>
<tr>
<td><strong>Action Taken</strong></td>
<td>None</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Mr Richard Mills</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Employment</strong></td>
<td>Director of Research, The National Autistic Society. Hon. Secretary and Research Director, Research Autism</td>
</tr>
<tr>
<td><strong>Personal pecuniary interest</strong></td>
<td>None</td>
</tr>
<tr>
<td><strong>Personal family interest</strong></td>
<td>None</td>
</tr>
<tr>
<td><strong>Non-personal pecuniary interest</strong></td>
<td>None</td>
</tr>
<tr>
<td>Personal non-pecuniary interest</td>
<td>Employed by the National Autistic Society and Research Autism</td>
</tr>
<tr>
<td>---------------------------------</td>
<td>---------------------------------------------------------------</td>
</tr>
<tr>
<td>Action Taken</td>
<td>None</td>
</tr>
</tbody>
</table>

**Ms Joan Panton**

<table>
<thead>
<tr>
<th>Employment</th>
<th>Representing service user and carer concerns</th>
</tr>
</thead>
<tbody>
<tr>
<td>Personal pecuniary interest</td>
<td>None</td>
</tr>
<tr>
<td>Personal family interest</td>
<td>None</td>
</tr>
<tr>
<td>Non-personal pecuniary interest</td>
<td>None</td>
</tr>
<tr>
<td>Personal non-pecuniary interest</td>
<td>None</td>
</tr>
<tr>
<td>Action Taken</td>
<td>None</td>
</tr>
</tbody>
</table>

**Ms Maggi Rigg**

<table>
<thead>
<tr>
<th>Employment</th>
<th>Cambian Group Advisory Board</th>
</tr>
</thead>
<tbody>
<tr>
<td>Personal pecuniary interest</td>
<td>None</td>
</tr>
<tr>
<td>Personal family interest</td>
<td>None</td>
</tr>
<tr>
<td>Non-personal pecuniary interest</td>
<td>None</td>
</tr>
<tr>
<td>Personal non-pecuniary interest</td>
<td>None</td>
</tr>
<tr>
<td>Action Taken</td>
<td>None</td>
</tr>
</tbody>
</table>

**Ms Anya Ustaszewski**

| Employment | Autism and Disability Awareness Trainer and Rights Advocate  
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Musician and Composer (Freelance)</td>
</tr>
<tr>
<td></td>
<td>Representing service user and carer concerns</td>
</tr>
<tr>
<td>Personal pecuniary interest</td>
<td>None</td>
</tr>
<tr>
<td>Personal family interest</td>
<td>None</td>
</tr>
<tr>
<td>Non-personal pecuniary interest</td>
<td>None</td>
</tr>
</tbody>
</table>
| Personal non-pecuniary interest| Steering Committee Member of London Autistic Rights Movement 
|            | Trustee of ASSERT B&H                                         |
|            | Trustee of AutreachIT                                         |
| Action Taken                   | None                                                          |

**National Collaborating Centre for Mental Health Staff**

**Professor Stephen Pilling**

<table>
<thead>
<tr>
<th>Employment</th>
<th>Director, National Collaborating Centre for Mental Health; Professor of Clinical Psychology and Clinical Effectiveness; Director, Centre for Outcomes Research and Effectiveness, University College London.</th>
</tr>
</thead>
</table>
| Personal pecuniary interest | Funding of £1,200,000 p.a. from NICE to develop clinical guidelines.  
|                          | Funding from British Psychological Society (2005 to 2011) £6,000,000 to establish the Clinical Effectiveness Programme at Centre for Outcomes Research and Effectiveness, UCL; with Professor P Fonagy and Professor S. Michie.  
|                          | Funding for the Dynamic Interpersonal Therapy (DIT) Competences Framework. |
| Personal family interest    | None                                                          |
| Non-personal pecuniary interest | RCT to evaluate multi-systemic therapy with Professor Peter Fonagy; Department of Health funding of £1,000,000 (2008 to 2012).  
<p>|                          | RCT to evaluate collaborative care for depression; with Professor D. Richards; Medical Research Council Funding of £2,200,000 (2008 to 2012). |</p>
<table>
<thead>
<tr>
<th>Name</th>
<th>Employment</th>
<th>Personal pecuniary interest</th>
<th>Personal family interest</th>
<th>Personal non-pecuniary interest</th>
<th>Non-personal pecuniary interest</th>
<th>Personal family interest</th>
<th>Personal non-pecuniary interest</th>
<th>Action Taken</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mr Nadir Cheema</td>
<td>Health Economist, NCCMH</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Ms Naomi Glover</td>
<td>Research Assistant, NCCMH</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Ms Flora Kaminski</td>
<td>Research Assistant, NCCMH</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Ms Katherine Leggett</td>
<td>Project Manager</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Dr Odette Megnin-Viggars</td>
<td>Systematic Reviewer, NCCMH (March 2010 onwards)</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Ms Sarah Stockton</td>
<td>Senior Information Scientist, NCCMH</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Dr Clare Taylor</td>
<td>Senior Editor, NCCMH</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Action Taken</td>
<td>None</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------</td>
<td>------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dr Amina Udechuku</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Employment</td>
<td>Systematic Reviewer, NCCMH (March 2010 – June 2011)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Personal pecuniary interest</td>
<td>None</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Personal family interest</td>
<td>None</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-personal pecuniary interest</td>
<td>None</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Personal non-pecuniary interest</td>
<td>None</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Action Taken</td>
<td>None</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
APPENDIX 3: SPECIAL ADVISORS TO THE GUIDELINE DEVELOPMENT GROUP

None
APPENDIX 4: STAKEHOLDERS WHO RESPONDED TO EARLY REQUESTS FOR EVIDENCE

None
APPENDIX 5: STAKEHOLDERS AND EXPERTS WHO SUBMITTED COMMENTS IN RESPONSE TO THE CONSULTATION DRAFT OF THE GUIDELINE

Stakeholders

To be inserted following consultation

Experts

To be inserted following consultation
APPENDIX 6: RESEARCHERS CONTACTED TO REQUEST INFORMATION ABOUT UNPUBLISHED OR SOON-TO-BE PUBLISHED STUDIES

Dr Adam Guastella
Professor Terry Brugha
Professor Peter Tyrer
Dr. Marco Bertelli
Professor Christopher McDougle
Dr Gary Remington
APPENDIX 7: ANALYTIC FRAMEWORK AND CLINICAL QUESTIONS

Assessment/ care pathways/experience of care

Clinical population

- Adults with autism
- Case identification/ diagnosis/ assessment

Sub-groups

- ID

People assessed as needing treatment

Organisation & delivery of care

- E1
- E2

Support for families &

- D1
- D2

Improvements in core and non-core autism symptoms

- Improved core autistic symptoms (social interaction, communication, rigid and repetitive interests and activities)
- Reduced global autistic behaviours
- Improved challenging behaviour
- Improved symptoms of coexisting conditions
- Improved subjective quality of life

Experience of care

- F1
- F2

Analysis/ care pathways/experience of care
### Case identification

<table>
<thead>
<tr>
<th>No.</th>
<th>Primary review questions</th>
</tr>
</thead>
<tbody>
<tr>
<td>A1</td>
<td>What signs or symptoms should prompt any professional who comes into contact with an adult with possible autism to consider referral for further assessment?</td>
</tr>
<tr>
<td>A2 &amp; A2a</td>
<td>What are the most effective methods/tools for case identification in adults with autism?</td>
</tr>
<tr>
<td></td>
<td>a. What amendments, if any, need to be made to the agreed methods for case identification to take into account individual variation [for example, gender, age, intellectual abilities (including cognitive strengths as well as difficulties), communication problems, developmental disorders, coexisting mental health disorders, physical problems including hyper/hypo-sensitivities, motor impairments, and visual and hearing impairments)?</td>
</tr>
</tbody>
</table>

### Diagnosis and assessment

<table>
<thead>
<tr>
<th>No.</th>
<th>Primary review questions</th>
</tr>
</thead>
</table>
| B1  | In adults with possible autism, what are the key components of, and the most effective structure for, a diagnostic assessment? To answer this question, consideration should be given to:  
- the nature and content of the clinical interview and observation (including an early developmental history where possible)  
- formal diagnostic methods/psychological instruments (including risk assessment)  
- biological measures  
- the setting(s) in which the assessment takes place  
- who the informant needs to be (to provide a developmental history). |
| B2  | When making a differential diagnosis of autism in adults, what amendments, if any, need to be made to the usual methods to make an:  
- assessment of autism itself in light of potential coexisting conditions?  
- assessment of the co-existing conditions (for example, common mental health disorders, ADHD, personality disorder, gender/identity disorders, eating disorders, Tourette Syndrome, and drug/alcohol misuse)? |
| B3  | What are the most effective methods for assessing an individual’s needs (for example, their personal, social, occupational, educational, and housing needs) for adults with autism? |
### Organisation & delivery of care

<table>
<thead>
<tr>
<th>No.</th>
<th>Primary review questions</th>
</tr>
</thead>
</table>
| E1  | What are the effective models for the delivery of care to people with autism including:  
|     | - the structure and design of care pathways?  
|     | - systems for the delivery of care (for example, case management)?  
|     | - advocacy services? |
| E2  | For adults with autism, what are the essential elements in the effective provision of:  
|     | - support services for the individual (including accessing and using services)?  
|     | - day care?  
|     | - residential care? |

### Experience of care

<table>
<thead>
<tr>
<th>No.</th>
<th>Primary review questions</th>
</tr>
</thead>
<tbody>
<tr>
<td>F1</td>
<td>For people with autism, what are their experiences of having autism, of access to services, and of treatment?</td>
</tr>
<tr>
<td>F2</td>
<td>For families, carers or significant others of people who have autism, what are their experiences of caring for people with autism, and what support is available for families, carers or significant others?</td>
</tr>
</tbody>
</table>
Treatment of autism in adults

Clinical population
Adults with autism

People assessed as needing treatment

C1, C2, C3, C4, C5

Cross-reference to existing NICE guideline

OR

New recommendation(s)

Autism-specific adaptations to treatment

C6

Autism in children

ADHD

Common Mental Health Disorders

OCD

Depression (update)

Current guideline

Autism in adult’s treatment goals:
- Reducing core and non-core autism symptoms
- Improving quality of life for adult with autism and families/carers
- Reducing symptoms of coexisting conditions
- Employment
**Interventions**

<table>
<thead>
<tr>
<th>No.</th>
<th>Primary review question</th>
</tr>
</thead>
<tbody>
<tr>
<td>C1</td>
<td>For adults with autism, what are the benefits and/or potential harms associated with different psychosocial interventions (for example, applied behavioural analysis, cognitive behavioural therapy, mentoring, social groups, and befriending schemes)?</td>
</tr>
<tr>
<td>C2</td>
<td>For adults with autism, what is the effectiveness of vocational and supported employment programmes?</td>
</tr>
<tr>
<td>C3</td>
<td>For adults with autism, what is the effectiveness of educational interventions (including specialist programmes, or support within mainstream education)?</td>
</tr>
<tr>
<td>C4</td>
<td>For adults with autism, what is the effectiveness of biomedical interventions (for example, dietary interventions, sensory integration, pharmacotherapy, and physical-environmental adaptations)?</td>
</tr>
</tbody>
</table>
| C5  | For adults with autism, is the effectiveness of interventions moderated by:  
  - the nature and severity of the condition?  
  - the presence of coexisting conditions?  
  - age?  
  - the presence of sensory sensitivities (including pain thresholds)?  
  - IQ?  
  - language level? |
| C6  | For adults with autism, what amendments, if any, need to be made to the current recommendations for psychosocial and pharmacological treatment (including the nature of drug interactions and side effects) for coexisting common mental health disorders? |
APPENDIX 8: REVIEW PROTOCOLS

Signs and symptoms review protocol

Table 1: Clinical review protocol for the review of signs and symptoms that should prompt a referral for further assessment

<table>
<thead>
<tr>
<th>Component</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Review question (s)</td>
<td>What signs or symptoms should prompt any professional who comes into contact with an adult with possible autism to consider referral for further assessment? (CQ-A1)</td>
</tr>
<tr>
<td>Chapter</td>
<td>5</td>
</tr>
<tr>
<td>Sub-section</td>
<td>5.2</td>
</tr>
<tr>
<td>Topic group</td>
<td>Assessment &amp; Case ID</td>
</tr>
<tr>
<td>Objectives</td>
<td>• To identify the signs and symptoms that would prompt referral for further diagnostic assessment.</td>
</tr>
<tr>
<td></td>
<td>• To suggest how recognition of autism can be improved</td>
</tr>
<tr>
<td>Criteria for considering studies</td>
<td>Adults and young people aged 18 years and older with suspected autism across the range of diagnostic groups (including atypical autism, Asperger’s syndrome and pervasive developmental disorder)</td>
</tr>
<tr>
<td>studies for the review</td>
<td>Consideration should be given to the specific needs of:</td>
</tr>
<tr>
<td></td>
<td>• people with coexisting conditions</td>
</tr>
<tr>
<td></td>
<td>• women</td>
</tr>
<tr>
<td></td>
<td>• older people</td>
</tr>
<tr>
<td></td>
<td>• people from black and minority ethnic groups</td>
</tr>
<tr>
<td></td>
<td>• transgender people</td>
</tr>
<tr>
<td>Population</td>
<td>Individuads with or without diagnosed autism</td>
</tr>
<tr>
<td>Comparison</td>
<td>Sensitivity, specificity, positive predictive value, negative predictive value, area under the curve</td>
</tr>
<tr>
<td>Critical outcomes</td>
<td>Cross-sectional, Systematic reviews</td>
</tr>
<tr>
<td>Study design</td>
<td>AEI, ASSIA, BEI, CDSR, CENTRAL, CINAHL, DARE, Embase, ERIC, HMIC, Medline, PsycINFO, Sociological Abstracts, SSA</td>
</tr>
<tr>
<td>Electronic databases</td>
<td>RCT, QE, OS, case-series. Inception of database up to 09/09/2011.</td>
</tr>
<tr>
<td>Date searched</td>
<td>Systematic reviews 1995 up to 09/09/2011.</td>
</tr>
<tr>
<td>The review strategy</td>
<td>To provide a GDG-consensus based narrative of signs and symptoms that should prompt a referral for specialist assessment as well as identify any amendments that need to be made to take into account individual variation</td>
</tr>
</tbody>
</table>

Note: autism = autism spectrum disorders; RCT = Randomised Controlled Trial; QE = Quasi-experimental; OS = Observational Study; AEI = Australian Education Index; ASSIA = Applied Social Services Index and Abstracts; BEI = British Education Index; CDSR = Cochrane Database of Systematic Reviews; CENTRAL = Cochrane Central Register of Controlled Trials; CINAHL = Cumulative Index to Nursing and Allied Health Literature; DARE = Database of Abstracts and Reviews of Effectiveness; Embase = Excerpta Medica database; ERIC = Education Resources in Curriculum; HMIC = Health Management Information Consortium; Medline = Biomedical Information Database; PsycINFO = Psychological Information Database; SSA = Social Services Abstracts
Case identification review protocol

Table 2: Clinical review protocol for the review of case identification tools

<table>
<thead>
<tr>
<th>Component</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Review question (s)</td>
<td>What are the most effective methods/tools for case identification in autism in adults? (CQ-A2)</td>
</tr>
<tr>
<td>Sub-question</td>
<td>What amendments, if any, need to be made to the agreed methods for case identification to take into account individual variation (for example, gender, age, intellectual abilities, including cognitive strengths as well as difficulties, communication problems, developmental disorders, coexisting mental health problems, physical health problems including hyper/hyposensitivities, motor impairments, and visual and hearing impairments)? (CQ-A2a)</td>
</tr>
<tr>
<td>Chapter</td>
<td>5</td>
</tr>
<tr>
<td>Sub-section</td>
<td>5.3</td>
</tr>
<tr>
<td>Topic group</td>
<td>Assessment &amp; Case ID</td>
</tr>
</tbody>
</table>
| Objectives                  | • To identify and evaluate case identification tools used in the recognition of autism  
• To suggest how recognition of autism can be improved                                                                                     |
| Criteria for considering studies for the review | Adults and young people aged 18 years and older with suspected autism across the range of diagnostic groups (including atypical autism, Asperger’s syndrome and pervasive developmental disorder).  
Consideration should be given to the specific needs of  
• people with coexisting conditions  
• women  
• older people  
• people from black and minority ethnic groups  
• transgender people.                                                                                                                            |
| • Population                | Case identification instruments (for example, the Autism-spectrum Quotient [AQ]; Social Communication Questionnaire [SCQ]; Autism Behaviour Checklist [ABC])                                                    |
| • Index test                | Case identification instruments                                                                                                                                                                              |
| • Comparison                | DSM or ICD diagnosis of autism                                                                                                                                                                                |
| • Critical outcomes         | Sensitivity: the proportion of true positives of all cases diagnosed with autism in the population  
Specificity: the proportion of true negatives of all cases not-diagnosed with autism in the population.                                                                                   |
| • Important, but not critical outcomes | Positive Predictive Value (PPV): the proportion of patients with positive test results who are correctly diagnosed.  
Negative Predictive Value (NPV): the proportion of patients with negative test results who are correctly diagnosed.  
Area under the Curve (AUC): are constructed by plotting the true positive rate as a function of the false positive rate for each threshold. |
| • Other outcomes            | Reliability (for example, inter-rater, test-retest)  
Validity (for example, construct, content)  
Internal consistency                                                                                                                                |
<p>| • Study design              | Cross-sectional                                                                                                                                                                                              |</p>
<table>
<thead>
<tr>
<th><strong>Include unpublished data?</strong></th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Restriction by date?</strong></td>
<td>No</td>
</tr>
<tr>
<td><strong>Minimum sample size</strong></td>
<td>N=10 per arm Excluding studies with &gt; 50% attrition from either arm of trial (unless adequate statistical methodology has been applied to account for missing data).</td>
</tr>
<tr>
<td><strong>Study setting</strong></td>
<td>Primary, secondary, tertiary, health and social care and healthcare settings (including prisons and forensic services) Others in which NHS services are funded or provided, or NHS professionals are working in multi-agency teams</td>
</tr>
<tr>
<td><strong>Electronic databases</strong></td>
<td>AEI, ASSIA, BEI, CDSR, CENTRAL, CINAHL, DARE, Embase, ERIC, HMIC, Medline, PsycINFO, Sociological Abstracts, SSA</td>
</tr>
<tr>
<td><strong>Date searched</strong></td>
<td>RCT, QE, OS, case series. Inception of database up to 09/09/2011. Systematic reviews. 1995 up to 09/09/2011</td>
</tr>
<tr>
<td><strong>Searching other resources</strong></td>
<td>Hand-reference searching of retrieved literature</td>
</tr>
<tr>
<td><strong>The review strategy</strong></td>
<td>To conduct pooled diagnostic accuracy meta-analyses on the sensitivity and specificity of case identification tools. This is dependent on available data from the literature. In the absence of this, a narrative review of case identification tools with be conducted and guided by a pre-defined list of consensus-based criteria (for example, the clinical utility of the tool, administrative characteristics, and psychometric data evaluating its sensitivity and specificity).</td>
</tr>
</tbody>
</table>

Note: autism = autism spectrum disorders; DSM = Diagnostic and Statistical Manual; ICD = International Classification of Diseases; RCT = Randomised Controlled Trial; QE = Quasi-experimental; OS = Observational Study; AEI = Australian Education Index; ASSIA = Applied Social Services Index and Abstracts; BEI = British Education Index; CDSR = Cochrane Database of Systematic Reviews; CENTRAL = Cochrane Central Register of Controlled Trials; CINAHL = Cumulative Index to Nursing and Allied Health Literature; DARE = Database of Abstracts and Reviews of Effectiveness; Embase = Excerpta Medica database; ERIC = Education Resources in Curriculum; HMIC = Health Management Information Consortium; Medline = Biomedical Information Database; PsycINFO = Psychological Information Database; SSA = Social Services Abstracts
**Assessment and diagnosis review protocol**

**Table 3: Clinical review protocol for assessment and diagnosis**

<table>
<thead>
<tr>
<th>Component</th>
<th>Description</th>
</tr>
</thead>
</table>
| Review question (s)        | In adults with possible autism, what are the key components of, and the most effective structure for, a diagnostic assessment? To answer this question, consideration should be given to:  
  - the nature and content of the clinical interview and observation (including an early developmental history where possible)  
  - formal diagnostic methods/ psychological instruments (including risk assessment)  
  - biological measures  
  - the setting(s) in which the assessment takes place  
  - who the informant needs to be (to provide a developmental history). (CQ- B1)  
  
  What are the most effective methods for assessing an individual’s needs (for example, their personal, social, occupational, educational, and housing needs) for adults with autism? (CQ – B3) |

| Sub-question               | When making a differential diagnosis of autism in adults, what amendments, if any, need to be made to the usual methods to make an assessment of autism itself in light of potential coexisting conditions (for example, common mental health disorders, ADHD, personality disorder, gender/identity disorders, eating disorder, Tourette’s syndrome, and drug/alcohol misuse)? (CQ- B2) |

| Chapter                    | 5 |
| Sub-section                | 5.4 |
| Topic Group                | Assessment & Case Identification |

**Objectives**  
- To identify the key components of an effective clinical interview to diagnose the presence and severity of autism in adults.  
- To evaluate the diagnostic accuracy of assessment tools which aid the diagnosis of autism in adults.  
- To identify what amendments, if any, need to be made to take into account individual differences (for example, coexisting conditions).  
- To identify the most effective methods for assessing an individual’s needs.  
- To evaluate an individual’s quality of life  
- To suggest how diagnosis of autism in adults can be improved  

**Criteria for considering studies for the review**  

| Population | Adults and young people aged 18 years and older with suspected autism across the range of diagnostic groups (including atypical autism, Asperger’s syndrome and pervasive developmental disorder )  
  Consideration should be given to the specific needs of:  
  - people with coexisting conditions  
  - women |
### Intervention
- Older people
- People from black and minority ethnic groups
- Transgender people.

### Index Test
- Formal assessments of the nature and severity of autism (including problem specification or diagnosis).

### Comparison
- DSM or ICD clinical diagnosis of autism (or equivalent)

### Critical outcomes
- **Reliability** (for example, inter-rater, test-retest)
- **Validity** (for example, construct, content)
- **Internal consistency**
- **Sensitivity**: the proportion of true positives of all cases diagnosed with autism in the population
- **Specificity**: the proportion of true negatives of all cases not-diagnosed with autism in the population

### Important, but not critical outcomes
- **Positive Predictive Value (PPV)**: the proportion of patients with positive test results who are correctly diagnosed.
- **Negative Predictive Value (NPV)**: the proportion of patients with negative test results who are correctly diagnosed.
- **Area under the Curve (AUC)**: are constructed by plotting the true positive rate as a function of the false positive rate for each threshold.

### Study design
- Cross-sectional

### Include unpublished data?
- No

### Restriction by date?
- No

### Minimum sample size
- N=10 per arm
- Exclude studies with > 50% attrition from either arm of trial (unless adequate statistical methodology has been applied to account for missing data).

### Study setting
- Primary, secondary, tertiary, health and social care and healthcare settings (including prisons and forensic services)
- Others in which NHS services are funded or provided, or NHS professionals are working in multi-agency teams

### Electronic databases
- AEI, ASSIA, BEI, CDSR, CENTRAL, CINAHL, DARE, Embase, ERIC, HMIC, Medline, PsycINFO, Sociological Abstracts, SSA

### Date searched
- RCT, QE, OS, case-series. Inception of database up to 09/09/2011.
- Systematic reviews. 1995 up to 09/09/2011.

### Searching other resources
- Hand-reference searching of retrieved literature

### The review strategy
- To provide a GDG-consensus based narrative identifying the key components of an effective clinical diagnostic interview (considering possible amendments due to individual variation).
- To conduct pooled diagnostic accuracy meta-analyses on the sensitivity and specificity, reliability and validity of assessment tools. This is dependent on available data from the literature. In the absence of this, a narrative review of assessment tools will be conducted and guided by a pre-defined list of consensus-based criteria (for
example, the clinical utility of the tool, administrative characteristics, and psychometric data evaluating its sensitivity, specificity, reliability and validity).

Note. autism = autism spectrum disorders; DSM = Diagnostic and Statistical Manual; ICD = International Classification of Diseases; RCT = Randomised Controlled Trial; QE = Quasi-experimental; OS = Observational Study; AEI = Australian Education Index; ASSIA = Applied Social Services Index and Abstracts; BEI = British Education Index; CDSR = Cochrane Database of Systematic Reviews; CENTRAL = Cochrane Central Register of Controlled Trials; CINAHL = Cumulative Index to Nursing and Allied Health Literature; DARE = Database of Abstracts and Reviews of Effectiveness; Embase = Excerpta Medica database; ERIC = Education Resources in Curriculum; HMIC = Health Management Information Consortium; Medline = Biomedical Information Database; PsycINFO = Psychological Information Database; SSA = Social Services Abstracts
Experience of care review protocol

<table>
<thead>
<tr>
<th>Component</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Review question(s)</td>
<td>For people with autism, what are their experiences of having autism, of access to services, and of treatment? (CQ-E1)</td>
</tr>
<tr>
<td></td>
<td>For families, carers or significant others of people who have autism, what are their experiences of caring for people with autism, and what support is available for families, carers or significant others? (CQ-E2)</td>
</tr>
<tr>
<td>Sub-question(s)</td>
<td>None</td>
</tr>
<tr>
<td>Chapter</td>
<td>4</td>
</tr>
<tr>
<td>Topic Group</td>
<td>Experience of care</td>
</tr>
<tr>
<td>Objectives</td>
<td>To identify the emerging themes for the experiences of individuals with autism and their families/carers in terms of the experience of autism and in terms of experiences of accessing services and of treatment</td>
</tr>
</tbody>
</table>
| Criteria for considering studies for the review | • Population Adults and young people aged 18 years and older with suspected autism across the range of diagnostic groups (including atypical autism, Asperger’s syndrome and pervasive developmental disorder), and their families and carers.  
  • Intervention None  
  • Comparison None  
  • Critical outcomes None specified - any narrative description of service user or carer experience of autism  
  • Study design Systematic reviews of qualitative studies, qualitative studies  
  • Include unpublished data? No  
  • Restriction by date? No  
  • Minimum sample size No minimum sample size  
  • Study setting Any setting  

Electronic databases ASSIA, CINAHL, Embase, HMIC, IBSS, Medline, PsycBOOKS, PsycEXTRA, PsycINFO, SSA, Sociological Abstracts

Date searched CINAHL, Embase, HMIC, Medline, PsycBOOKS, PsycEXTRA, PsycINFO: 01.01.1996 - 09.09.2011; ASSIA, IBSS, SSA, Sociological Abstracts: 01.01.1996 - 10.10.2011

Searching other resources Hand-reference searching of retrieved literature

The review strategy Thematic analysis of primary qualitative studies reporting experiences of individuals with autism and/or their families and carers

ASSIA = Applied Social Services Index and Abstracts; CINAHL = Cumulative Index to Nursing and Allied Health Literature; Embase = Excerpta Medica database; HMIC = Health Management Information Consortium; IBSS = International Bibliography of Social Sciences; Medline = Biomedical Information Database; PsycBOOKS = Psychological Information Database; PsycEXTRA = Grey literature database; PsycINFO = Psychological Information Database; SSA = Social Services Abstracts
**Psychosocial interventions review protocol**

**Table 4**: Clinical review protocol for the review of psychosocial interventions

<table>
<thead>
<tr>
<th>Component</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Review question</td>
<td>For adults with autism, what are the benefits and/or potential harms associated with different psychosocial interventions (for example, applied behavioural analysis, cognitive behavioural therapy, mentoring, social groups, and befriending schemes)? (CQ – C1)</td>
</tr>
<tr>
<td></td>
<td>For adults with autism, what is the effectiveness of vocational and supported employment programmes? (CQ – C2)</td>
</tr>
<tr>
<td></td>
<td>For adults with autism, what is the effectiveness of educational interventions (including specialist programmes, or support within mainstream education, or educational software, etc.)? (CQ – C3)</td>
</tr>
<tr>
<td>Sub-question</td>
<td>For adults with autism, is the effectiveness of interventions moderated by:</td>
</tr>
<tr>
<td></td>
<td>* the nature and severity of the condition?</td>
</tr>
<tr>
<td></td>
<td>* the presence of coexisting conditions?</td>
</tr>
<tr>
<td></td>
<td>* age?</td>
</tr>
<tr>
<td></td>
<td>* the presence of sensory sensitivities (including pain thresholds)?</td>
</tr>
<tr>
<td></td>
<td>* IQ?</td>
</tr>
<tr>
<td></td>
<td>* language level? (CQ – C5)</td>
</tr>
<tr>
<td></td>
<td>For adults with autism, what amendments, if any, need to be made to the current recommendations for psychosocial and pharmacological treatment (including the nature of drug interactions and side effects) for coexisting common mental health disorders? (CQ–C6)</td>
</tr>
</tbody>
</table>

**Chapter** 6  
**Topic group** Psychological/ Educational/ Social Interventions  
**Objectives** To evaluate the clinical effectiveness of psychosocial interventions for autism.  
**Criteria for considering studies for the review**
### Population

Adults and young people aged 18 years and older with suspected autism across the range of diagnostic groups (including atypical autism, Asperger’s syndrome and pervasive developmental disorder).

Consideration should be given to the specific needs of:
- people with coexisting conditions
- women
- older people
- people from black and minority ethnic groups
- transgender people

Excluded groups include:
- children (< 18 years of age)

HOWEVER it was decided based on GDG consensus that where primary data from an adult population was absent it may be valid to extrapolate from an autism population with a mean age of 15 years or above.

For interventions concerned with the management of behaviour, and where data from adult autism populations was not sufficient, the GDG decided that extrapolating from an intellectual disabilities population was valid.

### Intervention(s)

- **Psychosocial interventions aimed at behaviour management** (for example, applied behaviour analysis, behavioural therapies, cognitive behavioural therapy, social learning)
- **Communication** (for example, augmentative and alternative communication, facilitated communication, picture exchange system)
- **Vocational/employment interventions** (for example, vocational rehabilitation programmes, individual supported employment)

### Comparison

Treatment-as-usual, waitlist control, other active interventions

### Critical outcomes

Outcomes involving core features of autism (social interaction, communication, repetitive interests/activities); overall autistic behaviour; management of challenging behaviour; outcomes involving treatment of coexisting conditions

### Study design

- **RCTs**

The GDG agreed by consensus that where there were no RCTs found in the evidence search, or the results from the RCTs were inconclusive, that the following studies would be included in the review of evidence:
- observational
- quasi-experimental
- case series

### Include unpublished data?

Yes but only where:
- the evidence was accompanied by a trial report containing sufficient detail to properly assess the quality of the data
- the evidence was submitted with the understanding that data from the study and a summary of the study’s characteristics will be published in the full guideline. Therefore, the
GDG should not accept evidence submitted as commercial in confidence. However, the GDG should recognise that unpublished evidence submitted by investigators, might later be retracted by those investigators if the inclusion of such data would jeopardise publication of their research.

<table>
<thead>
<tr>
<th>Restriction by date?</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Minimum sample size</td>
<td></td>
</tr>
</tbody>
</table>
  - RCT/observational/quasi-experimental studies:- N=10 per arm (ITT)
  - Case series studies:- N=10 in total
  Exclude studies with > 50% attrition from either arm of trial (unless adequate statistical methodology has been applied to account for missing data). |
| Study setting |  
  - Primary, secondary, tertiary, health and social care and healthcare settings (including prisons and forensic services)
  - Others in which NHS services are funded or provided, or NHS professionals are working in multi-agency teams |
| Electronic databases | AEI, AMED, ASSIA, BEI, CDSR, CENTRAL, CINAHL, DARE, Embase, ERIC, HMIC, Medline, PsycINFO, Sociological Abstracts, SSA |
| Searching other resources | Hand-reference searching of retrieved literature |
| Review strategy |  
  - The initial aim is to conduct a meta-analysis evaluating the clinical effectiveness of the interventions. However, in the absence of adequate data, the literature will be presented via a narrative synthesis of the available evidence.
  - Narratively review literature that takes into consideration any amendments due to common mental health disorders.
  - Consider subgroup meta-analyses that takes into account the effectiveness of interventions as moderated by:-
    - the nature and severity of the condition
    - the presence of coexisting conditions?
    - age
    - the presence of sensory sensitivities (including pain thresholds)
    - IQ
    - language level |

Note: autism=autism spectrum disorders; DSM = Diagnostic and Statistical Manual; ICD = International Classification of Diseases; RCT = Randomised Controlled Trial; QE = Quasi-experimental; OS = Observational Study; AEI = Australian Education Index; AMED = Allied and Complementary Medicine; ASSIA = Applied Social Services Index and Abstracts; BEI = British Education Index; CDSR = Cochrane Database of Systematic Reviews; CENTRAL = Cochrane Central Register of Controlled Trials; CINAHL = Cumulative Index to Nursing and Allied Health Literature; DARE = Database of Abstracts and Reviews of Effectiveness; Embase = Excerpta Medica database; ERIC = Education Resources in Curriculum; HMIC = Health Management Information Consortium; Medline = Biomedical Information Database; PsycINFO = Psychological Information Database; SSA = Social Services Abstracts
## Biomedical interventions review protocol

### Table 5: Clinical review protocol for the review of biomedical interventions

<table>
<thead>
<tr>
<th>Component</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Review question</strong></td>
<td>For adults with autism, what is the effectiveness of biomedical interventions (for example, dietary interventions, pharmacotherapy, and physical-environmental adaptations)? (CQ – C4)</td>
</tr>
</tbody>
</table>
| **Sub-question**         | For adults with autism, is the effectiveness of interventions moderated by:  
                          - the nature and severity of the condition?  
                          - the presence of coexisting conditions?  
                          - age?  
                          - the presence of sensory sensitivities (including pain thresholds)?  
                          - IQ?  
                          - language level? (CQ – C5)  

For adults with autism, what amendments, if any, need to be made to the current recommendations for psychosocial and pharmacological treatment (including the nature of drug interactions and side effects) for coexisting common mental health disorders? (CQ-C6) |

### Chapter 7

**Topic group**: Biomedical Interventions

**Objectives**: To evaluate the clinical effectiveness of biomedical interventions for autism.
### Population
Adults and young people aged 18 years and older with suspected autism across the range of diagnostic groups (including atypical autism, Asperger’s syndrome and pervasive developmental disorder).

Consideration should be given to the specific needs of:
- people with coexisting conditions
- women
- older people
- people from black and minority ethnic groups
- transgender people

Excluded groups include:
- children (< 18 years of age)

HOWEVER – the GDG made a consensus-based decision that we would need to extrapolate from literature involving children (<18 years) for interventions where there was not sufficient evidence from an adult population and where the mechanisms of biomedical interventions were judged by the GDG to be equivalent in children and adults.

For interventions concerned with the management of behaviour, and where data from adult autism populations was not sufficient, the GDG decided that extrapolating from an intellectual disability population was valid.

### Intervention(s)
- **Pharmacotherapy** (for example, antipsychotics, antidepressants, anticonvulsants)
- **Vitamins and dietary supplements** (for example, omega-3 fatty acid supplements, vitamin B12, vitamin A)
- **Hormones** (for example, oxytocin, secretin, melatonin)

### Comparison
Placebo-controlled, other active interventions

### Critical outcomes
Outcomes involving core features of autism (social interaction, communication, repetitive interests/activities); overall autistic behaviour; symptom severity/improvement; management of challenging behaviour; outcomes involving treatment of coexisting conditions; side effects.

### Study design
- **RCTs**

The GDG agreed by consensus that where there were no RCTs found in the evidence search, or the results from the RCTs were inconclusive, that the following studies would be included in the review of evidence:
- observational
- quasi-experimental
- case series

### Include unpublished data?
Yes but only where:
- the evidence was accompanied by a trial report containing sufficient detail to properly assess the quality of the data
- the evidence was submitted with the understanding that data from the study and a summary of the study’s characteristics will be published in the full guideline. Therefore, the GDG should not accept evidence submitted as commercial in confidence. However, the GDG
should recognise that unpublished evidence submitted by investigators, might later be retracted by those investigators if the inclusion of such data would jeopardise publication of their research.

<table>
<thead>
<tr>
<th>Restriction by date?</th>
<th>No</th>
</tr>
</thead>
</table>
| Minimum sample size  | - RCT/observational/quasi-experimental studies: N=10 per arm (ITT)  
- Case series studies: N=10 in total  
Exclude studies with > 50% attrition from either arm of trial (unless adequate statistical methodology has been applied to account for missing data). |
| Study setting         | - Primary, secondary, tertiary, health and social care and healthcare settings (including prisons and forensic services)  
- Others in which NHS services are funded or provided, or NHS professionals are working in multi-agency teams |
| Electronic databases  | AEI, AMED, ASSIA, BEI, CDSR, CENTRAL, CINAHL, DARE, Embase, ERIC, HMIC, Medline, PsycINFO, Sociological Abstracts, SSA |
| Searching other resources | Hand-reference searching of retrieved literature |
| The review strategy   | - The initial aim is to conduct a meta-analysis evaluating the clinical effectiveness of the interventions. However, in the absence of adequate data, the literature will be presented via a narrative synthesis of the available evidence.  
- Narrative review of the literature that takes into consideration any amendments due to common mental health disorders.  
- Consider subgroup meta-analyses that takes into account the effectiveness of interventions as moderated by:  
  - the nature and severity of the condition  
  - the presence of coexisting conditions  
  - age  
  - the presence of sensory sensitivities (including pain thresholds)  
  - IQ  
  - language level |

Note. autism=autism spectrum disorders; DB = Database; DSM = Diagnostic and Statistical Manual; ICD = International Classification of Diseases; RCT = Randomised Controlled Trial; QE = Quasi-experimental; OS = Observational Study; SR = Systematic Review; AEI = Australian Education Index; AMED = Allied and Complementary Medicine; ASSIA = Applied Social Services Index and Abstracts; BEI = British Education Index; CDSR = Cochrane Database of Systematic Reviews; CENTRAL = Cochrane Central Register of Controlled Trials; CINAHL = Cumulative Index to Nursing and Allied Health Literature; DARE = Database of Abstracts and Reviews of Effectiveness; Embase = Excerpta Medica database; ERIC = Education Resources in Curriculum; HMIC = Health Management Information Consortium; Medline = Biomedical Information Database; PsycINFO = Psychological Information Database; SSA = Social Services Abstracts
Support for families and carers review protocol

Table 6: Clinical review protocol for the review of direct support for families & carers and the role of the family in supporting the delivery of interventions

<table>
<thead>
<tr>
<th>Component</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Review question(s)</td>
<td>What information and day-to-day support do families and carers need: - during the initial period of assessment and diagnosis? - when treatment and care is provided (for example, telephone helpline, information packs, advocates or respite care, interpreters and other language tools)? - during periods of crisis? (CQ – D1) What role can families and carers play in supporting the delivery of interventions for people with autism? (CQ – D2)</td>
</tr>
<tr>
<td>Sub-question(s)</td>
<td>None</td>
</tr>
<tr>
<td>Chapter</td>
<td>6</td>
</tr>
<tr>
<td>Sub-section</td>
<td>6.9</td>
</tr>
<tr>
<td>Topic Group</td>
<td>Experience of care</td>
</tr>
</tbody>
</table>
| Objectives        | - To determine what support services and information is needed for families and carers of people with autism at the point of diagnosis as well as throughout the care pathway.  
- To specify and evaluate the role of the family and carer in supporting an individual with autism receiving an intervention. |
| Criteria for considering studies for the review |                                                                                                                                                                                                                                                                                                                                            |
| • Population      | The families and carers of: - Adults and young people aged 18 years and older with suspected autism across the range of diagnostic groups (including atypical autism, Asperger’s syndrome and pervasive developmental disorder)  
HOWEVER it was decided based on GDG consensus that where primary data from an adult population was absent it may be valid to extrapolate from families and carers of autistic young people with a mean age of 15 years or above.  
- For interventions concerned with parental support/psychoeducation, and where data from adult autism populations was not sufficient, the GDG decided that extrapolating from an intellectual disability population was valid. |
| • Intervention(s) | - Psycho-education  
- Interventions to support family involvement in the process of care  
- Psychosocial interventions for families (for example, support groups for families and carers) |
| • Comparison      | Treatment-as-usual, waitlist control, other active interventions                                                                                                                                                                                                                                                                           |
| • Critical outcomes | Family focused measures  
- Family members satisfaction and well-being |
### Study design

- **RCTs**

The GDG agreed by consensus that where there were no RCTs found in the evidence search, or the results from the RCTs were inconclusive, that the following studies would be included in the review of evidence:

- observational
- quasi-experimental
- case series

### Include unpublished data?

Yes but only where:

- the evidence was accompanied by a trial report containing sufficient detail to properly assess the quality of the data
- the evidence was submitted with the understanding that data from the study and a summary of the study’s characteristics will be published in the full guideline. Therefore, the GDG should not accept evidence submitted as commercial in confidence. However, the GDG should recognise that unpublished evidence submitted by investigators, might later be retracted by those investigators if the inclusion of such data would jeopardise publication of their research.

### Restriction by date?

No

### Minimum sample size

- RCT/Observational/Quasi-Experimental Studies: N=10 per arm (ITT)
- Case Series Studies: N=10 in total

Exclude studies with > 50% attrition from either arm of trial (unless adequate statistical methodology has been applied to account for missing data).

### Study setting

- Primary, secondary, tertiary, health and social care and healthcare settings (including prisons and forensic services)
- Others in which NHS services are funded or provided, or NHS professionals are working in multi-agency teams

### Electronic databases

- AEI, AMED, ASSIA, BEI, CDSR, CENTRAL, CINAHL, DARE, Embase, ERIC, HMIC, Medline, PsycINFO, Sociological Abstracts, SSA

### Date searched


### Searching other resources

Hand-reference searching of retrieved literature

### The review strategy

- Narrative review of the literature that takes into consideration any amendments due to common mental health disorders.
Consider subgroup meta-analyses that takes into account the effectiveness of interventions as moderated by:
- the nature and severity of the condition
- the presence of co-existing conditions
- age
- the presence of sensory sensitivities (including pain thresholds)
- IQ

Note: AEI = Australian Education Index; AMED = Allied and Complementary Medicine; ASSIA = Applied Social Services Index and Abstracts; BEI = British Education Index; CDSR = Cochrane Database of Systematic Reviews; CENTRAL = Cochrane Central Register of Controlled Trials; CINAHL = Cumulative Index to Nursing and Allied Health Literature; DARE = Database of Abstracts and Reviews of Effectiveness; Embase = Excerpta Medica database; ERIC = Education Resources in Curriculum; HMIC = Health Management Information Consortium; Medline = Biomedical Information Database; PsycINFO = Psychological Information Database; SSA = Social Services Abstracts
### Organisation and delivery of care review protocol

#### Table 7: Clinical review protocol for the review of organisation and delivery of care

<table>
<thead>
<tr>
<th>Component</th>
<th>Description</th>
</tr>
</thead>
</table>
| **Review question** | What are the effective models for the delivery of care to people with autism including:  
- the structure and design of care pathways?  
- systems for the delivery of care (for example, case management)?  
- advocacy services? (CQ – E1)  
For adults with autism, what are the essential elements in the effective provision of:  
- support services for the individual (including accessing and using services)?  
- day care?  
- residential care? (CQ – E2) |
| **Sub-question** | None |
| **Chapter** | 8 |
| **Topic group** | None |
| **Objectives** | To evaluate the components and effectiveness of different models for the delivery of care |
| **Criteria for considering studies for the review** |  
- **Population**  
Adults and young people aged 18 years and older with suspected autism across the range of diagnostic groups (including atypical autism, Asperger’s syndrome and pervasive developmental disorder).  
Consideration should be given to the specific needs of:  
- people with coexisting conditions  
- women  
- older people  
- people from black and minority ethnic groups  
- transgender people  
Excluded groups include:  
- children (< 18 years of age)  
Where data from adult autism populations was not sufficient, the GDG decided that extrapolating from an intellectual disabilities population was valid. |
| **Intervention(s)** |  
- **Case co-ordination models** (for example, case management; collaborative care; key worker systems)  
- **Advocacy and support services**  
- **Multi-disciplinary team models** (for example, specialist assessment teams; specialist community teams; assertive community treatment teams)  
- **Models of care delivery** (for example, stepped care, clinical care pathways)  
- **Day care services** (including the model and content of services) |
<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Residential care (including the model and content of services)</td>
</tr>
<tr>
<td></td>
<td>Comparison</td>
</tr>
<tr>
<td></td>
<td>Critical outcomes</td>
</tr>
<tr>
<td></td>
<td>Study design</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Minimum sample size</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Study setting</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Electronic databases</td>
</tr>
<tr>
<td></td>
<td>Searching other resources</td>
</tr>
<tr>
<td></td>
<td>The review strategy</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Note: autism = autism spectrum disorders; DSM = Diagnostic and Statistical Manual; ICD = International Classification of Diseases; RCT = Randomised Controlled Trial; QE = Quasi-experimental; OS = Observational Study; AEI = Australian Education Index; AMED = Allied and Complementary Medicine; ASSIA = Applied Social Services Index and Abstracts; BEI = British Education Index; CDSR = Cochrane Database of Systematic Reviews; CENTRAL = Cochrane Central Register of Controlled Trials; CINAHL = Cumulative Index to Nursing and Allied Health Literature; DARE = Database of Abstracts and Reviews of Effectiveness; Embase = Excerpta Medica database; ERIC = Education Resources in Curriculum; HMIC = Health Management Information Consortium; Medline = Biomedical Information Database; PsycINFO = Psychological Information Database; SSA = Social Services Abstracts
APPENDIX 9: SEARCH STRATEGIES FOR THE IDENTIFICATION OF CLINICAL STUDIES

Search strategies

The search strategies should be referred to in conjunction with information set out in Section 3.5.2. Each search was constructed using the groups of terms as set out in Box 1. The full set of terms constructed for use in Medline follow on.
### Box 1: Summary of systematic search strategies

<table>
<thead>
<tr>
<th>Review question</th>
<th>Search type</th>
<th>Search construction</th>
<th>Study design limit</th>
<th>Databases / date range</th>
</tr>
</thead>
<tbody>
<tr>
<td>CQ - A1, A2/A2a; CQ - B1, B2, B3; CQ - C1, C2, C3, C4, C5; C6; CQ - D1, D2; CQ - E1, E2; CQ - F1, F2;</td>
<td>Generic</td>
<td>[(ASC terms) AND (SR/RCT/QE/OS/case-series study design filters)]</td>
<td>SR, RCT, QE, OS, case-series</td>
<td>Databases searched: AMED, ASSIA, Australian Education Index, British Education Index, CDSR, CENTRAL, CINAHL, DARE, Embase, Education Resources in Curriculum, HMIC, Medline, PsycINFO, Sociological Abstracts, Social Services Abstracts. Date range searched: RCT, QE, OS, case-series: Inception of database up to 09.09.2011. SR: 1995 up to 09.09.2011.</td>
</tr>
</tbody>
</table>

Note. CQ = Review Question; Generic = broad search comprising terms for population and study design only; ASC = Autism spectrum conditions; SR = Systematic Review; RCT = Randomised Controlled Trial; QE = Quasi-experimental; OS = Observational Study. Note. See Appendix 7 for full detail of review questions.

### Chapter: Experience of Care

<table>
<thead>
<tr>
<th>Review question</th>
<th>Search type</th>
<th>Search construction</th>
<th>Study design limit</th>
<th>Databases / date range</th>
</tr>
</thead>
<tbody>
<tr>
<td>CQ - F1, F2</td>
<td>Generic, supplements search for quantitative evidence [above]</td>
<td>[(ASC terms) AND (Qualitative/survey study design filters)]</td>
<td>Qualitative, Survey</td>
<td>Databases searched: CINAHL, Embase, HMIC, Medline, PsycINFO, PsycEXTRA, PsycBOOKS. Date range searched: 01.01.1996 - 09.09.2011. ASSIA, IBSS, Social Services Abstracts, Sociological Abstracts. Date range searched: 01.01.1996 - 10.10.2011.</td>
</tr>
</tbody>
</table>

Note. CQ = Review Question; Generic = broad search comprising terms for population and study design only; ASC = Autism spectrum conditions. Note. See Appendix 7 for full detail of review questions.
### Review question

<table>
<thead>
<tr>
<th>Review question</th>
<th>Search type</th>
<th>Search construction</th>
<th>Study design limit</th>
<th>Databases / date range</th>
</tr>
</thead>
</table>

Note. CQ = Review Question; Focused = specific search comprising terms for population, intervention and study design; SR = Systematic Review; RCT = Randomised Controlled Trial; QE = Quasi-experimental; OS = Observational Study.

Note. See Appendix 7 for full detail of review questions.

**Chapter: Biomedical interventions**
### Review question | Search type | Search construction | Study design limit | Databases / date range |
---|---|---|---|---|

Note. CQ = Review Question; Focused = specific search comprising terms for population, intervention and study design; SR = Systematic Review; RCT = Randomised Controlled Trial; QE = Quasi-experimental; OS = Observational Study. Note. See Appendix 7 for full detail of review questions.

### Chapter: Organisation and Delivery of Care

| Review question | Search type | Search construction | Study design limit | Databases / date range |
---|---|---|---|---|

Note. CQ = Review Question; Focused = specific search comprising terms for population, intervention and study design; SR = Systematic Review; RCT = Randomised Controlled Trial; QE = Quasi-experimental; OS = Observational Study. Note. See Appendix 7 for full detail of review questions.
1.1 Population Search terms

a) Autistic spectrum conditions (ASC) - population search terms

Medline – Ovid SP interface

1. asperger syndrome/or autistic disorder/or child development disorders, pervasive/ or rett syndrome/
2. (asperger$ or autis$ or cerebroatrophic hyperammonemia$ or (kanner$ adj (disorder$ or syndrome$)) or (pervasive$ adj2 (development$ or neurodevelopment$)) or pddnos or pdd nos or (rett$ adj (disorder$ or syndrome$))).ti,ab.
3. or/1-2

b) Intellectual disability – population search terms

Medline – Ovid SP interface

1. developmental disabilities/ or disabled persons/ or "education of mentally retarded"/ or education, special/ or exp learning disorders/ or exp mental retardation/ or mentally disabled persons/ or phenylketonurias/
2. ((developmental$ or intellect$ or language or learning or neurodevelopmental or phonologic$ or speech or vocabular$) adj2 delay$).ti,ab.
3. ((developmental$ or intellect$ or language or learning or neurodevelopmental or phonologic$ or speech or vocabular$) adj2 (defect$ or deficien$ or deficit$ or difficult$ or disorder$ or disturbanc$ or dysfunction$ or impair$ or problem$ or subnormal$ or sub$ normal$)).ti,ab.
4. ((disabilit$ or disabled) adj3 (adult$ or aged or client$ or consumer$ or elderly or female$ or geriatric$ or individual$ or latelife or late life or male$1 or men or middle aged or midlife or mid life or old or older or patient$ or people$ or person$ or population$ or seniors or women$)).ti,ab.
5. ((disabilit$ or disabled) adj3 (communicat$ or defect$ or deficien$ or deficit$ or developmental$ or dysfunction$ or functional or impair$ or multiple or intellect$ or language or learning or neurodevelopmental$ or phonologic$ or receptive or speech or subnormal$ or sub$ normal$ or vocabular$)).ti,ab.
6. ((down$ adj2 syndrom$) or (fragile adj3 syndrome) or oligophren$ or phenylketonuria$).ti,ab.
7. ((handicap$ or handi cap$ or retard$1 or retardates or retarded) adj3 (developmental$ or functional or motor$ or multiple or neurodevelopmental or psychomotor or severe$)).ti,ab.
1.2 Question specific search strategies

a) Interventions aimed at behavioural management (sub-section of CQ-C1,C4)

CQ – C1: For adults with autism, what are the benefits and/or potential harms associated with different psychosocial interventions (e.g. applied behavioural analysis, cognitive behavioural therapy, mentoring, social groups, and befriending schemes)?

CQ – C4: For adults with autism, what is the effectiveness of biomedical interventions (e.g. dietary interventions, pharmacotherapy, and physical-environmental adaptations)?

Area searched: subsection of CQs – search limited to interventions aimed at behaviour management only

Medline – Ovid SP interface

1. behaviour/ or behavior control/
2. learning disorders/rh or mental retardation/rh
3. (adaptive adj (behavio?r$ or skill$)).ti,ab.
4. (behav$ adj3 (challenging or difficult$ or destructiv$ or disruptiv$ or disturbance$ or dysfunction$ or problem$)).ti,ab.
5. ((behav$ or challenging or destructiv$ or disruptiv$ or disturbance$ or dysfunction$ or interfering) adj2 (disorder$ or problem$ or symptom$ or syndrome$)).ti,ab.
6. ((decreas$ or improv$ or lower$ or reduc$) adj2 (behav$ or destructive$ or disruptive$ or interfering symptom$)).ti,ab.
7. aggression/ or exp anger/ or *"attention deficit and disruptive behavior disorders"/ or hostility/ or restraint, physical/ or self-injurious behaviour/ or self mutilation/ or violence/
8. (agitat$ or aggress$ or anger$ or hostil$ or rebel$ or retaliat$).ti,ab.
9. (biting or headbut$ or head but$ or hitting or kick$ or scream$ or spit or spitting or tantrum$ or troublesome).ti,ab.
10. (compulsive$ or repetitive$ or stereotypy).ti,ab.
11. (physical$ adj2 restrain$).ti,ab.
12. (selfharm$ or self harm$ or selfinjur$ or self injur$ or selfmutilat$ or self mutilat$ or selfdestruct$ or self destruct$ or (self adj2 cut$) or cutt$ or selfimmolat$ or self immolat$ or selfinflict$ or self inflict$ or automutilat$ or auto mutilat$).ti,ab.
13. or/1-12
14. exp behavior therapy/
15. “reinforcement (psychology)”/
16. (((behav$ or cognitiv$) adj3 (analy$ or interven$ or manag$ or program$ or therap$ or treat$ or workshop$ or work shop$)) or (behav$ adj2 (modif$ or control$)) or cbt).ti,ab.
17. (model?ing or prompting or reinforcement or re inforcement or self evaluat$).ti,ab.
18. (self care/ and (cognit$ or behavio?r$ or metacognit$ or recover$).tw,hw. ) or (selfinstruct$ or selfmanag$ or selfattribut$ or (self$ adj (instruct$ or manag$ or attribution$)) or (rational$ adj3 emotiv$) or (rational adj (living or psychotherap$ or therap$)) or (ret adj (psychotherap$ or therap$)) or rebt or (active directive adj (psychotherap$ or therap$))).ti,ab.
19. (*activities of daily living/ and ((ed or rh or th).fs. or (educat$ or program$ or skill$ or teach$ or therap$).hw.)) or toilet training/
20. “education of mentally retarded”/
21. (self care or ((bathing or dressing or eating or feeding or grooming or homemak$ or hygien$ or leisure or toilet$ or undress$) adj3 (educat$ or instruct$ or interven$ or learn$ or program$ or promot$ or skill$ or taught$ or teach$ or train$))).ti,ab.
22. (((independen$ or life or living or (self adj (care or protect$)) or social or survival) adj2 (educat$ or instruct$ or interven$ or learn$ or program$ or skill$ or taught$ or teach$ or train$))).ti,ab.
23. (((communicat$ or interact$ or interpersonal$ or language$) adj3 (educat$ or instruct$ or interven$ or learn$ or program$ or skill$ or taught$ or teach$ or train$)) or social learn$).ti,ab.
24. ((adrenocorticotropic hormone/ or exp amantadine/ or exp anti-anxiety agents/ or exp anticonvulsants/ or exp antidepressive agents/ or exp antipsychotic agents/ or exp central nervous system stimulants/ or exp chelating agents/ or exp cholinesterase inhibitors/ or galantamine/ or melatonin/ or oxytocin/ or secretin/) or (diet/ or exp dietary supplements/ or exp minerals/ or exp vitamins/) or exp testosterone/) and behav$.ti,ab,hw.
25. or/14-24
26. or/13,25

b) Support for families and carers (CQ – D1)

CQ – D1: What information and day-to-day support do families and carers need:
* during the initial period of assessment and diagnosis?
when treatment and care is provided (e.g. telephone helpline, information packs, advocates or respite care, interpreters and other language tools)?

during periods of crisis?

Medline – Ovid SP interface

1. caregivers/ or family/ or family health/ or family relations/ or intergenerational relations/ or exp maternal behaviour/ or exp parent-child relations/ or parenting/ or exp parents/ or paternal behavior/ or professional-family relations/ or sibling relations/

2. (carer$1 or caregiv$ or care taker$ or caretaker$ or custodian$ or family or families or father$ or guardian$ or mother$ or parent$ or spouse$ or stepparent$ or ((communicat$ or conversation$ or familiar or interact$ or language or speech) adj2 partner$)).ti,ab.

3. or/1-2

4. audiovisual aids/ or books, illustrated/ or books/ or books, illustrated/ or cellular phone/ or computer user training/ or computers/ or education, distance/ or educational technology/ or electronic mail/ or exp health education/ or health knowledge, attitudes, practice/ or exp health promotion/ or hotlines/ or information dissemination/ or information seeking behaviour/ or exp internet/ or multimedia/ or pamphlets/ or software/ or exp tape recording/ or teaching materials/ or teledicine/ or telephone/ or therapy, computer assisted/ or exp videodisc recording/ or writing/

5. day care/

6. family health/

7. friends/ or self help groups/ or exp social environment/

8. home care services/ or home care services, hospital based/ or exp home nursing/ or home health aides/or social support/

9. interpersonal relations/ or professional-family relations/ or social facilitation/

10. ed.fs. and 1

11. (advocate$ or advocacy).ti,ab.

12. ((audio$ or cd$1 or cd rom$ or cdrom$ or computer$ or cyber$ or dvd$1 or electronic$ or floppy or handheld or hand held or interactive or internet$ or manual$1 or mobile or online or palmtop or palm top or pc$1 or phone$1 or read$1 or reading or sms$1 or telephone$ or text or texts or texting or video$ or virtual or web$ or written or www) adj3 (approach$ or assist$ or coach$ or club$ or class$ or help$ or interven$ or learn$ or module$ or program$ or psychotherap$ or rehab$ or strateg$ or support$ or therap$ or treat$ or workshop$ or work shop$)).ti,ab.

13. (book$1 or booklet$ or brochure$ or educat$ or information$ or instruct$ or knowledge or leaflet$ or manual$1 or material$ or multimedia or multimedia or ((oral or printed or written) adj3 inform$) or pamphlet$ or poster$ or psycho educat$ or psychoeducat$ or teach$ or train$ or video$ or workbook$ or work book$).ti,ab.
14. (call in or call line$ or help line$ or helpline$ or hotline$ or hot line$ or phone in or phonein or (caller$1 adj3 (interven$ or program$ or therapis$ or treat$))).ti,ab.

15. (((carer$1 or caregiv$ or care taker$ or caretaker$ or custodian$ or family or families or father$ or guardian$ or mother$ or parent$ or spouse$ or stepparent$ or ((communicat$ or conversation$ or familiar or interact$ or language or speech) adj2 partner$)) adj3 (approach$ or assist$ or coach$ or club$ or class$ or group$ or help$ or interven$ or learn$ or module$ or program$ or psychotherap$ or rehab$ or skill$ or strateg$ or support$ or therapis$ or treat$ or workshop$ or work shop$)).ti,ab.

16. (((carer$1 or caregiv$ or care taker$ or caretaker$ or custodian$ or family or families or father$ or guardian$ or mother$ or parent$ or spouse$ or stepparent$ or ((communicat$ or conversation$ or familiar or interact$ or language or speech) adj2 partner$)) adj3 burden$).ti,ab.

17. (((carer$1 or caregiv$ or care taker$ or caretaker$ or custodian$ or family or families or father$ or guardian$ or mother$ or parent$ or spouse$ or stepparent$ or ((communicat$ or conversation$ or familiar or interact$ or language or speech) adj2 partner$)) adj5 (protect$ or relief or service$)).ti,ab.

18. (((carer$1 or caregiv$ or care taker$ or caretaker$ or custodian$ or family or families or father$ or guardian$ or mother$ or parent$ or spouse$ or stepparent$ or ((communicat$ or conversation$ or familiar or interact$ or language or speech) adj2 partner$)) adj8 (communicat$ or conversation$ or interact$)).ti,ab.

19. (((carer$1 or caregiv$ or care taker$ or caretaker$ or custodian$ or family or families or father$ or guardian$ or mother$ or parent$ or spouse$ or stepparent$ or ((communicat$ or conversation$ or familiar or interact$ or language or speech) adj2 partner$)) adj10 (communicat$ or interact$ or interpersonal or inter personal or talk$) adj10 (approach$ or assist$ or coach$ or club$ or class$ or group$ or help$ or interven$ or learn$ or module$ or program$ or psychotherap$ or rehab$ or strateg$ or support$ or therapis$ or treat$)).ti,ab.

20. day care.ti,ab.


22. ((home adj2 (care$ or nurs$ or service$)) or respite).ti,ab.

23. (interpreter$ or ((communicat$ or language or learning$ or speech) adj2 tool$) or special educator$).ti,ab.

24. (mutual adj (help or aid or support$)).ti,ab.

25. (self help$ or self help$ or social support or (support$ adj2 (group$ or network$ or professional$))).ti,ab.

26. or/1-25

c) Residential care (sub-section of CQ – E2)
CQ-E2: For adults with ASC, what are the essential elements in the effective provision of:
* support services for the individual (including accessing and using services)?
* day care?
* residential care?

Area searched: subsection of CQ – search limited to residential care only

Medline – Ovid SP interface

1. deinstitutionalization/ or home care services / or home care aides/ or home care services, hospital-based/ or exp home nursing/ or exp housing/ or independent living programs/ or institutionalization/ or long term care/ or exp residential facilities/ or residential treatment/
2. accommodation.ti,ab.
3. (aged care facilit$ or ((care or group$ or nursing or old age) adj2 home$)).ti,ab.
4. apartment$.ti,ab.
5. ((campus$ or cluster$ or dispersed) adj3 (accomodat$ or centre$ or center$ or communit$ or complex$ or facilit$ or home$ or hous$ or institution$ or living or model$ or neighbour$ or place$1 or placement$ or resident$ or setting$ or unit$)).ti,ab.
6. (communit$ adj3 (accomodat$ or campus$ or complex$ or facilit$ or home$ or hous$ or institution$ or living or place$1 or placement$ or resident$ or unit$)).ti,ab.
7. (communit$ adj2 (discharg$ or move$ or moving or relocat$)).ti,ab.
8. concept hous$.ti,ab.
9. (deinstitutionali$ or institutionali$).ti,ab.
10. developmental cent$.ti,ab.
11. (disabled adj2 communit$).ti,ab.
12. dwelling$.ti,ab.
13. (flatemate or housemate$ or ((flat or house) adj mate$)).ti,ab.
14. ((home$1 or hous$ or living or resident$) adj4 (assist$ or support$)).ti,ab.
15. (home adj2 (care$ or nur$ or service$)).ti,ab.
16. (hostel$ or shelter$).ti,ab.
17. housing.ti,ab.
18. (independ?n$ adj3 (accomodat$ or care or centre$ or center$ or communit$ or complex$ or facilit$ or home$ or hous$ or institution$ or living or placement$ or resident$ or setting$ or unit$)).ti,ab.
19. ((intentional or congregat$ or village$) adj2 (communit$ or setting$)).ti,ab.
20. ((institution$ or intensive or out of$1) adj3 (care$ or living or placement$ or place$1 or resident$ or setting$)).ti,ab.
21. (live in$1 or (out adj2 home$)).ti,ab.
1.3 Study design search filters

a) Systematic review search filter – adapted from a filter designed by the Health Information Research Unit of the McMaster University, Ontario.

Medline – Ovid SP interface

1. meta analysis/ or "review literature as topic"/
2. (exp databases, bibliographic/ or (((electronic or computer$ or online) adj database$) or bids or cochrane or embase or isi citation or medline or metasynthesis or metanalysis or metasynthesis or meta synthes$) or meta syntheses$).ti,ab)
3. (systematic$.ti,ab,sh. or systematic$.ti,ab)
4. (metaanalysis$ or metaanal$ or metareview$ or meta review$ or metasynthesis$ or meta synthes$).ti,ab
5. (research adj (review$ or integration)).ti,ab.
6. reference list$.ab,
7. bibliograph$.ab.
8. published studies.ab.
9. relevant journals.ab.
10. selection criteria.ab.
11. (data adj (extraction or synthesis)).ab.
12. (handsearch$ or (hand or manual) adj search$)).ti,ab.
13. (mantel haenszel or peto or dersimonian or der simonian).ti,ab.
16. (fixed effect$ or random effect$).ti,ab.
17. ((pool$ or combined or combining) adj2 (data or trials or studies or results)).ti,ab.
18. or/1-17

**b) RCT search filter – adapted from a filter designed by the Health Information Research Unit of the McMaster University, Ontario.**

Medline – Ovid SP interface

1. exp clinical trial/ or cross-over studies/ or double-blind method/ or placebos/ or random allocation/ or randomization/ or randomized controlled trials as topic/ or single-blind method/
2. (clinical adj2 trial$).ti,ab.
3. (crossover or cross over).ti,ab.
4. (((single$ or doubl$ or trebl$ or tripl$) adj2 blind$) or mask$ or dummy or singleblind$ or doubleblind$ or trebleblind$ or tripleblind$).ti,ab.
5. (placebo$ or random$).ti,ab.
6. animals/ not humans/
7. or/1-5 not 6

**c) Quasi-experimental study filter – developed in house.**

Medline – Ovid SP interface

1. (((nonequivalent or non equivalent) adj3 control$) or posttest$ or post test$ or pre test$ or pretest$ or quasi$ or timeseries or time series).tw.

**d) Observational and case series study filter – developed in house.**

Medline– Ovid SP interface

1. case-control studies/ or cohort studies/ or cross-sectional studies/ or epidemiologic studies/ or follow-up studies/ or longitudinal studies/ or prospective studies/ or retrospective studies/
2. cohort$.ti,ab.
3. (case$ adj2 (control$ or series)).ti,ab.
4. or/1-3

**e) Qualitative / survey literature study filter – developed in house.**

Medline – Ovid SP interface
1. anthropology, cultural/ or cluster analysis/ or ethnology/ or focus
groups/ or interview/ or exp interviews as topic/ or narration/ or
nursing methodology research/ or observation/ or personal
narratives/ or qualitative research/ or sampling studies/ or exp tape
recording/ or videodisc recording/
2. action research.ti,ab.
3. (((audio or tape or video$) adj2 record$) or audiorecord$ or
taperecord$ or videorecord$ or videotap$).ti,ab.
4. (colaiazzi$ or giorgi$ or glaser or heidegger$ or hermeneutic$ or
husserl$ or spiegelberg$ or strauss$).ti,ab.
5. (constant adj (comparative or comparison)).ti,ab.
6. (content analy$ or (field adj (note$ or record$ or research$ or stud$)) or
fieldnote$).ti,ab.
7. (critical social$ or ethical enquiry or (pilot testing and survey) or
shadowing or ((philosophical or social) adj research$)).ti,ab.
8. (cross case analys$ or (meta adj (ethno$ or narrative$ or overview or
synthes$ or summar$ or stud$)) or metaethno$ or metanarrative$ or
metaoverview$ or metasynthes$ or metasummar$ or metastud$).ti,ab.
9. (data adj1 saturat$).ti,ab.
10. discourse analys?s.ti,ab.
11. (ethno$ or emic or etic or heuristic or phenomenolog$ or qualitative or
semiotics).ti,ab.
12. ((focus adj2 (group$ or sampl$)) or ((life or lived) adj experience$) or
narrat$).ti,ab.
13. (focus$ or structured) adj2 interview$.ti,ab.
14. (grounded adj (theor$ or study or research or studies)).ti,ab.
15. human science.ti,ab.
16. (maximum variation or snowball).ti,ab.
17. (merleau or theoretical sampl$ or ricoeur or spiegelberg$).ti,ab.
18. (participant$ or nonparticipant$) adj3 observ$.ti,ab.
19. purpos$ sampl$.ti,ab.
20. (story or stories or storytell$ or story tell$).ti,ab.
21. testimon$.ti,ab.
22. (structured categor$ or unstructured categor$).ti,ab.
23. (thematic$ adj3 analys$ or themes).ti,ab.
24. (van kaam$ or van manen ).ti,ab.
25. or/1-24
26. health care surveys/ or exp health surveys/
27. (question$ or survey$).ti,ab.
28. attitude/ or exp attitude to health/
29. (attitude$ or experienc$).ti,ab.
30. or/26-27 and or/28-29
31. [TEXTWORD SEARCHES FOR ASC POPULATION SEARCH TERMS]
and (attitude$ or experienc$ or needs or opinion$ or perception$ or
perspective$ or preference$ or satisf$ or view$) and (adult$1 or
attendee$ or attender$ or client$ or consumer$ or individuals or
inpatient$ or men or minorities or outpatient$ or participant$ or patient$ or people or population or public or respondent$ or subjects or survivor$ or women or user$ or care giver$ or caregiver$ or carer$ or (care adj (giver$ or manager$ or worker$)) or family or families or father$ or guardian$ or mother$ or parent$)).ti.
32. ((adult$1 or attendee$ or attender$ or client$ or consumer$ or individuals or inpatient$ or men or minorities or outpatient$ or participant$ or patient$ or people or population or public or respondent$ or subjects or survivor$ or women or user$ or (care giver$ or caregiver$ or carer$ or (care adj (giver$ or manager$ or worker$)) or family or families or father$ or guardian$ or mother$ or parent$) adj2 (attitude$ or experience$ or needs or opinion$ or perception$ or perspective$ or preference$ or satisf$ or view$)).ti,ab.
33. or/31-32
34. or/25,30,33
APPENDIX 10: QUALITY CHECKLISTS FOR CLINICAL STUDIES AND REVIEWS

The methodological quality of each study was evaluated using NICE checklists (NICE, 2009e). The checklists for systematic reviews and for RCTs are reproduced below (for other checklists and further information about how to complete each checklist, see The Guidelines Manual [NICE, 2009e]). The completed checklists can be found in Appendix 16.

Methodology checklist: systematic reviews and meta-analyses

<table>
<thead>
<tr>
<th>Study identification</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Include author, title, reference, year of publication</td>
<td></td>
</tr>
</tbody>
</table>

Guideline topic:  
Checklist completed by:  

<table>
<thead>
<tr>
<th>SCREENING QUESTIONS</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>In a well-conducted, relevant systematic review:</td>
<td>Circle one option for each question</td>
</tr>
<tr>
<td>The review addresses an appropriate and clearly focused question that is relevant to the guideline review question</td>
<td>Yes  No  Unclear</td>
</tr>
<tr>
<td>The review collects the type of studies you consider relevant to the guideline review question</td>
<td>Yes  No  Unclear</td>
</tr>
<tr>
<td>The literature search is sufficiently rigorous to identify all the relevant studies</td>
<td>Yes  No  Unclear</td>
</tr>
<tr>
<td>Study quality is assessed and reported</td>
<td>Yes  No  Unclear</td>
</tr>
<tr>
<td>An adequate description of the methodology used is included, and the methods used are appropriate to the question</td>
<td>Yes  No  Unclear</td>
</tr>
</tbody>
</table>
Methodology checklist: RCTs

<table>
<thead>
<tr>
<th>Study identification Include author, title, reference, year of publication</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Guideline topic:</td>
<td>Review question no:</td>
</tr>
<tr>
<td>Checklist completed by:</td>
<td></td>
</tr>
</tbody>
</table>

**A. Selection bias (systematic differences between the comparison groups)**

| A1 | An appropriate method of randomisation was used to allocate participants to treatment groups (which would have balanced any confounding factors equally across groups) | Yes | No | Unclear | N/A |
| A2 | There was adequate concealment of allocation (such that investigators, clinicians and participants cannot influence enrolment or treatment allocation) | Yes | No | Unclear | N/A |
| A3 | The groups were comparable at baseline, including all major confounding and prognostic factors | Yes | No | Unclear | N/A |

Based on your answers to the above, in your opinion was selection bias present? If so, what is the likely direction of its effect?

- Low risk of bias
- Unclear/unknown risk
- High risk of bias

**Likely direction of effect:**

**B. Performance bias (systematic differences between groups in the care provided, apart from the intervention under investigation)**

| B1 | The comparison groups received the same care apart from the intervention(s) studied | Yes | No | Unclear | N/A |
| B2 | Participants receiving care were kept ‘blind’ to treatment allocation | Yes | No | Unclear | N/A |
| B3 | Individuals administering care were kept ‘blind’ to treatment allocation | Yes | No | Unclear | N/A |

Based on your answers to the above, in your opinion was performance bias present? If so, what is the likely direction of its effect?

- Low risk of bias
- Unclear/unknown risk
- High risk of bias

**Likely direction of effect:**

**C. Attrition bias (systematic differences between the comparison groups with respect to loss of participants)**
### C1
All groups were followed up for an equal length of time (or analysis was adjusted to allow for differences in length of follow-up)  
<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
<th>Unclear</th>
<th>N/A</th>
</tr>
</thead>
</table>

### C2
a. How many participants did not complete treatment in each group?  
b. The groups were comparable for treatment completion (that is, there were no important or systematic differences between groups in terms of those who did not complete treatment)  
<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
<th>Unclear</th>
<th>N/A</th>
</tr>
</thead>
</table>

### C3
a. For how many participants in each group were no outcome data available?  
b. The groups were comparable with respect to the availability of outcome data (that is, there were no important or systematic differences between groups in terms of those for whom outcome data were not available).  
<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
<th>Unclear</th>
<th>N/A</th>
</tr>
</thead>
</table>

Based on your answers to the above, in your opinion was attrition bias present? If so, what is the likely direction of its effect?  
- Low risk of bias  
- Unclear/unknown risk  
- High risk of bias  

Likely direction of effect:  

### D. Detection bias (bias in how outcomes are ascertained, diagnosed or verified)

<table>
<thead>
<tr>
<th>D1</th>
<th>The study had an appropriate length of follow-up</th>
<th>Yes</th>
<th>No</th>
<th>Unclear</th>
<th>N/A</th>
</tr>
</thead>
<tbody>
<tr>
<td>D2</td>
<td>The study used a precise definition of outcome</td>
<td>Yes</td>
<td>No</td>
<td>Unclear</td>
<td>N/A</td>
</tr>
<tr>
<td>D3</td>
<td>A valid and reliable method was used to determine the outcome</td>
<td>Yes</td>
<td>No</td>
<td>Unclear</td>
<td>N/A</td>
</tr>
<tr>
<td>D4</td>
<td>Investigators were kept ‘blind’ to participants’ exposure to the intervention</td>
<td>Yes</td>
<td>No</td>
<td>Unclear</td>
<td>N/A</td>
</tr>
<tr>
<td>D5</td>
<td>Investigators were kept ‘blind’ to other important confounding and prognostic factors</td>
<td>Yes</td>
<td>No</td>
<td>Unclear</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Based on your answers to the above, in your opinion was detection bias present? If so, what is the likely direction of its effect?  
- Low risk of bias  
- Unclear/unknown risk  
- High risk of bias  

Likely direction of effect:
APPENDIX 11: SEARCH STRATEGIES FOR THE IDENTIFICATION OF HEALTH ECONOMICS EVIDENCE

Search strategies for the identification of health economics and quality-of-life studies.

The search strategies should be referred to in conjunction with information set out in Section 3.6.1. Each search was constructed using the groups of terms as set out in Box 1. The full set of terms constructed for use in Medline follow on.
**Box 1: Summary of systematic health economic search strategies**

<table>
<thead>
<tr>
<th>Review question</th>
<th>Search type</th>
<th>Search construction</th>
<th>Study design limit</th>
<th>Databases / date range</th>
</tr>
</thead>
<tbody>
<tr>
<td>CQ - A1, A2/A2a; CQ - B1, B2, B3; CQ - C1, C2, C3, C4, C5, C6 CQ - D1, D2; CQ - E1, E2; CQ - F1, F2;</td>
<td>Generic</td>
<td>(ASC terms) AND (HE/QoL study design filter)</td>
<td>HE/QoL</td>
<td>Databases searched: Econlit, Embase, HTA database, Medline, NHS EED, PsycINFO Date range searched: 1996 up to 09.09.2011.</td>
</tr>
</tbody>
</table>

Note. CQ = Review Question; Generic = broad search comprising terms for population and study design only; ASC = Autism spectrum conditions; HE = health economics; QoL = quality of life.

Note. See Appendix 7 for full detail of review questions.

**Chapter: Psychological and psychosocial interventions (includes support for families and carers)**
### Review question

| CQ - C1 [subsection of question – search limited to psychosocial interventions aimed at behaviour management only] | Focused, supplements generic search for evidence on ASC | [(Intellectual disability terms) AND (behaviour management terms) AND (HE/QoL study design filter)] | HE/QoL | Databases searched: Econlit, Embase, HTA database, Medline, NHS EED, PsycINFO  
Date range searched: 1996 up to 09.09.2011. |
|---|---|---|---|---|
| CQ - D1 | Focused, supplements generic search for evidence on ASC | [(Intellectual disability terms) AND (support for family and carer terms) AND (HE/QoL study design filter)] | HE/QoL | Databases searched: Econlit, Embase, HTA database, Medline, NHS EED, PsycINFO  
Date range searched: 1996 up to 09.09.2011. |

Note. CQ = Review Question; Focused = specific search comprising terms for population, intervention and study design; ASC = Autism spectrum conditions; HE = health economics; QoL = quality of life.  
Note. See Appendix 7 for full detail of review questions.

#### Chapter: Biomedical interventions
### Chapter: Organisation and Delivery of Care

<table>
<thead>
<tr>
<th>Review question</th>
<th>Search type</th>
<th>Search construction</th>
<th>Study design limit</th>
<th>Databases / date range</th>
</tr>
</thead>
</table>

Note. CQ = Review Question; Focused = specific search comprising terms for population, intervention and study design; ASC = Autism spectrum conditions; HE = health economics; QoL = quality of life. Note. See Appendix 7 for full detail of review questions.
1.1 Population Search terms

a) Autistic spectrum conditions (ASC) - population search terms

Medline – Ovid SP interface

1. asperger syndrome/or autistic disorder/or child development disorders, pervasive/or rett syndrome/

2. (asperger$ or autis$ or cerebroatrophic hyperammonemia$ or (kanner$ adj (disorder$ or syndrome$)) or (pervasive$ adj2 (development$ or neurodevelopment$)) or pddnos or pdd nos or (rett$ adj (disorder$ or syndrome$))).ti,ab.

3. or/1-2

b) Intellectual disability – population search terms

Medline – Ovid SP interface

1. developmental disabilities/ or disabled persons/ or "education of mentally retarded"/ or education, special/ or exp learning disorders/ or exp mental retardation/ or mentally disabled persons/ or phenylketonurias/

2. ((developmental$ or intellect$ or language or learning or neurodevelopmental or phonologic$ or speech or vocabular$) adj2 delay$).ti,ab.

3. ((developmental$ or intellect$ or language or learning or neurodevelopmental or neurodevelopment$) adj2 (defect$ or deficien$ or deficit$ or difficult$ or disorder$ or disturbanc$ or dysfunction$ or impair$ or problem$ or subnormal$ or sub$ normal$)).ti,ab.

4. ((disabilit$ or disabled) adj3 (adult$ or aged or client$ or consumer$ or elderly or female$ or geriatric$ or individual$ or latelife or late life or male$1 or men or middle aged or midlife or mid life or old or older or patient$ or people$ or person$ or population$ or seniors or women)).ti,ab.

5. ((disabilit$ or disabled) adj3 (communicat$ or defect$ or deficien$ or deficit$ or developmental$ or dysfunction$ or functional or impair$ or multiple or intellect$ or language or learning or neurodevelopmental$ or phonologic$ or receptive or speech or subnormal$ or sub$ normal$ or vocabular$)).ti,ab.

6. ((down$ adj2 syndrom$) or (fragile adj3 syndrome) or oligophren$ or phenylketonuria).ti,ab.

7. ((handicap$ or handi cap$ or retard$1 or retardates or retarded) adj3 (developmental$ or functional or motor$ or multiple or neurodevelopmental or psychomotor or severe)).ti,ab.

8. ((handicap$ or handi cap$ or retard$1 or retardates or retarded) adj3 (adult$ or aged or client$ or consumer$ or elderly or female$ or geriatric$ or individual$ or latelife or late life or male$1 or men or middle aged or midlife or mid life or old or older or patient$ or people$ or person$ or population$ or seniors or women)).ti,ab.
9. (mental$ adj2 (defect$ or deficien$ or deficit$ or disable$ or disabilit$ or impair$ or incapacit$ or subnormal$ or sub$1 normal$)).ti,ab.
10. (special adj (educat$ or need$)).ti,ab.
12. or/1-11

1.2 Question specific search strategies

a) Interventions aimed at behavioural management (sub-section of CQ-C1,C4)

CQ – C1: For adults with autism, what are the benefits and/or potential harms associated with different psychosocial interventions (e.g. applied behavioural analysis, cognitive behavioural therapy, mentoring, social groups, and befriending schemes)?

CQ – C4: For adults with autism, what is the effectiveness of biomedical interventions (e.g. dietary interventions, pharmacotherapy, and physical-environmental adaptations)?

Area searched: subsection of CQs – search limited to interventions aimed at behaviour management only

Medline – Ovid SP interface

1. behaviour/ or behavior control/
2. learning disorders/rh or mental retardation/rh
3. (adaptive adj (behavio?r$ or skill$)).ti,ab.
4. (behav$ adj3 (challenging or difficult$ or destructiv$ or disruptiv$ or disturbance$ or dysfunction$ or problem$)).ti,ab.
5. ((behav$ or challenging or destructiv$ or disruptiv$ or disturbance$ or dysfunction$ or interfering) adj2 (disorder$ or problem$ or symptom$ or syndrome$)).ti,a b.
6. ((decreas$ or improv$ or lower$ or reduc$) adj2 (behav$ or destructive$ or disruptive$ or interfering symptom$)).ti,ab.
7. aggression/ or exp anger/ or *’’attention deficit and disruptive behavior disorders’’/ or hostility/ or restraint, physical/ or self-injurious behaviour/ or self mutilation/ or violence/
8. (agitat$ or aggress$ or anger$ or hostil$ or rebel$ or retaliat$).ti,ab.
9. (biting or headbut$ or head but$ or hitting or kick$ or scream$ or spit or spitting or tantrum$ or troublesome).ti,ab.
10. (compulsive$ or repetitive$ or stereotypy$).ti,ab.
11. (physical$ adj2 restrain$).ti,ab.
12. (selfharm$ or self harm$ or selfinjur$ or self injur$ or selfmutilat$ or self mutilat$ or selfdestruct$ or self destruct$ or (self adj2 cut$) or cut$ or selfimmolat$ or self immolat$ or selfinflict$ or self inflict$ or automutilat$ or auto mutilat$).ti,ab.
13. or/1-12
14. exp behavior therapy/
15. “reinforcement (psychology)” /
16. (((behav$ or cognitiv$) adj3 (analy$ or interven$ or manag$ or program$ or therap$ or treat$ or workshop$ or work shop$)) or (behav$ adj2 (modif$ or control$)) or cbt).ti,ab.
17. (model$ing or prompting or reinforcement or re inforcement or self evaluat$).ti,ab.
18. (self care/ and (cognit$ or behavio?r$ or metacognit$ or recover$).tw,hw. ) or (selfinstruct$ or selfmanag$ or selfattribut$ or (self$ adj (instruct$ or manag$ or attribution$))) or (rational$ adj3 emotiv$) or (rational adj (living or psychotherap$ or therap$)) or (ret adj (psychotherap$ or therap$)) or rebt or (active directive adj (psychotherap$ or therap$))).ti,ab.
19. (*activities of daily living/ and ((ed or rh or th).fs. or (educat$ or program$ or skill$ or teach$ or therap$).hw.)) or toilet training/
20. “education of mentally retarded” /
21. (self care or ((bathing or dressing or eating or feeding or grooming or homemak$ or hygien$ or leisure or toilet$ or undress$) adj3 (educat$ or instruct$ or interven$ or learn$ or program$ or promot$ or skill$ or taught$ or teach$ or train$))).ti,ab.
22. ((independen$ or life or living or (self adj (care or protect$)) or social or survival) adj2 (educat$ or instruct$ or interven$ or learn$ or program$ or skill$ or taught or teach$ or train$)).ti,ab.
23. (((communicat$ or interact$ or interpersonal$ or language$) adj3 (educat$ or instruct$ or interven$ or learn$ or program$ or skill$ or taught$ or teach$ or train$)) or social learn$).ti,ab.
24. ((adrenocorticotropic hormone/ or exp amantadine/ or exp anti-anxiety agents/ or exp anticonvulsants/ or exp antidepressive agents/ or exp antipsychotic agents/ or exp central nervous system stimulants/ or exp chelating agents/ or exp cholinesterase inhibitors/ or galantamine/ or melatonin/ or oxytocin/ or secretin/) or (diet/ or exp dietary supplements/ or exp minerals/ or exp vitamins/) or exp testosterone/) and behav$.ti,ab,hw.
25. or/14-24
26. or/13,25

b) Support for family and carers (CQ – D1)

CQ – D1: What information and day-to-day support do families and carers need:–
* during the initial period of assessment and diagnosis?
* when treatment and care is provided (e.g. telephone helpline, information packs, advocates or respite care, interpreters and other language tools)?
* during periods of crisis?

Medline – Ovid SP interface
1. caregivers/ or family/ or family health/ or family relations/ or intergenerational relations/ or exp maternal behaviour/ or exp parent-child relations/ or parenting/ or exp parents/ or paternal behavior/ or professional-family relations/ or sibling relations/

2. (carer$1 or caregiv$ or caretaker$ or custodian$ or family or families or father$ or guardian$ or mother$ or parent$ or spouse$ or stepparent$ or ((communicat$ or conversation$ or familiar or interact$ or language or speech) adj2 partner$)).ti,ab.

3. or/1-2

4. audiovisual aids/ or books, illustrated/ or books/ or books, illustrated/ or cellular phone/ or computer user training/ or computers/ or education, distance/ or educational technology/ or electronic mail/ or exp health education/ or health knowledge, attitudes, practice/ or exp health promotion/ or hotlines/ or information dissemination/ or information seeking behaviour/ or exp internet/ or multimedia/ or pamphlets/ or software/ or exp tape recording/ or teaching materials/ or telemedicine/ or telephone/ or therapy, computer assisted/ or exp videodisc recording/ or writing/

5. day care/

6. family health/

7. friends/ or self help groups/ or exp social environment/

8. home care services/ or home care services, hospital based/ or exp home nursing/ or home health aides/ or social support/

9. interpersonal relations/ or professional-family relations/ or social facilitation/

10. ed.fs. and 1

11. (advocate$ or advocacy).ti,ab.

12. ((audio$ or cd$1 or cd rom$ or cdrom$ or computer$ or cyber$ or dvd$1 or electronic$ or floppy or handheld or hand held or interactive or internet$ or manual$1 or mobile or online or palmtop or palm top or pc$1 or phone$1 or read$1 or reading or sms$1 or telephone$ or text or texts or texting or video$ or virtual or web$ or written or www) adj3 (approach$ or assist$ or coach$ or club$ or class$ or help$ or interven$ or learn$ or module$ or program$ or psychotherap$ or rehab$ or strateg$ or support$ or therap$ or treat$ or workshop$ or work shop$)).ti,ab.

13. (book$1 or booklet$ or brochure$ or educat$ or information$ or instruct$ or knowledge or leaflet$ or manual$1 or material$ or multi media or multimedia or ((oral or printed or written) adj3 inform$) or pamphlet$ or poster$ or psycho educat$ or psychoeducat$ or teach$ or train$ or video$ or workbook$ or work book$).ti,ab.

14. (call in or callline$ or call line$ or help line$ or helpline$ or hotline$ or hot line$ or phone in or phonein or (caller$1 adj3 (interven$ or program$ or therap$ or treat$))).ti,ab.

15. ((carer$1 or caregiv$ or care taker$ or caretaker$ or custodian$ or family or families or father$ or guardian$ or mother$ or parent$ or spouse$ or stepparent$ or ((communicat$ or conversation$ or familiar or interact$ or language or speech) adj2 partner$))).ti,ab.
c) Residential care (sub-section of CQ – E2)

CQ-E2: For adults with ASC, what are the essential elements in the effective provision of:
* support services for the individual (including accessing and using services)?
* day care?
* residential care?

Area searched: subsection of CQ – search limited to residential care only
Medline – Ovid SP interface

1. deinstitutionalization/ or home care services / or home care aides/ or home care services, hospital-based/ or exp home nursing/ or exp housing/ or independent living programs/ or institutionalization/ or long term care/ or exp residential facilities/ or residential treatment/
2. accommodation.ti,ab.
3. (aged care facilit$ or ((care or group$ or nursing or old age) adj2 home$)).ti,ab.
4. apartment$t,ti,ab.
5. ((campus$ or cluster$ or dispersed) adj3 (accomodat$ or centre$ or center$ or communit$ or complex$ or facilit$ or home$ or hous$ or institution$ or living or model$ or neighbour$ or place$1 or placement$ or resident$ or setting$ or unit$)).ti,ab.
6. (communit$ adj3 (accomodat$ or campus$ or complex$ or facilit$ or home$ or hous$ or institution$ or living or place$1 or placement$ or resident$ or unit$)) .ti,ab.
7. (communit$ adj2 (discharg$ or move$ or moving or relocat$)).ti,ab.
8. concept hous$.ti,ab.
9. (deinstitutionali$ or institutionalali$).ti,ab.
10. developmental cent$.ti,ab.
11. (disabled adj2 communit$).ti,ab.
12. dwelling$.ti,ab.
13. (flatemate or housemate$ or ((flat or house) adj mate$)).ti,ab.
14. ((home$1 or hous$ or living or resident$) adj4 (assist$ or support$)).ti,ab.
15. (home adj2 (care$ or nurs$ or service$)).ti,ab.
16. (hostel$ or shelter$).ti,ab.
17. housing.ti,ab.
18. (independ?n$ adj3 (accomodat$ or care or centre$ or center$ or communit$ or complex$ or facilit$ or home$ or hous$ or institution$ or living or placement$ or resident$ or setting$ or unit$)).ti,ab.
19. ((intentional or congregat$ or village$) adj2 (communit$ or setting$)).ti,ab.
20. ((institution$ or intensive or out of$1) adj3 (care$ or living or placement$ or place$1 or resident$ or setting$)).ti,ab.
21. (live in$1 or (out adj2 home$)).ti,ab.
22. (((long term or extended) adj care) or long stay).ti,ab.
23. ((rent$ or own$) adj2 (accommodat$ or home$1 or hous$ or resident$)).ti,ab.
24. (residence$ or residential).ti,ab.
25. (resident$ adj3 (accomodat$ or care or centre$ or center$ or communit$ or complex$ or facilit$ or home$ or hous$ or institution$ or living or model$ or neighbour$ or place$1 or placement$ or program$ or provision$ or service$ or setting$ or unit$)).ti,ab.
26. ((special or support$) adj2 living).ti,ab.
27. (staffed adj3 (accomodat$ or centre$ or center$ or complex$ or facilit$ or home$ or hous$ or institution$ or living$ or model$ or neighbourhood$ or placement$ or resident$ or setting$ or unit$)).ti,ab.
28. [TEXTWORD SEARCHES FOR INTELLECTUAL DISABILITY POPULATION SEARCH TERMS] adj5 (accommodat$ or home$1 or hous$ or living or resident$).ti,ab.

29. or/1-28

1.3 Study design search filters

a) Health economics and quality of life search filter – an adaptation of a filter designed by the Centre for Reviews and Dissemination (CRD) (2007).

Medline – Ovid SP interface

1. exp budgets/ or exp “costs and cost analysis”/ or economics/ or exp economics, hospital/ or exp economics, medical/ or economics, nursing/ or economics, pharmaceutical/ or exp “fees and charges”/ or exp resource allocation/ or value of life/

2. (budget$ or cost$ or econom$ or expenditure$ or fee or fees or financ$ or fund or funds or funding$ or funded or (expenditure$ not energy) or pharmacoeconomic$ or price or prices or pricing or ration or rations or rationing$ or rationed or resource$ allocate$ or saving or (value adj2 (monetary or money))).ti,ab.

3. ec.fs. and [SUBJECT HEADING SEARCH FOR ASD POPULATION]

4. or/1-3

5. exp decision theory/ or markov chains/ or exp models, economic/ or *models, organizational/ or *models, theoretical/ or monte carlo method/

6. (decision adj (analy$ or model$ or tree$)).ti,ab.

7. economic model$.ti,ab.

8. markov.ti,ab.

9. monte carlo.ti,ab.

10. or/5-9

11. quality-adjusted life years/ or sickness impact profile/

12. (((disability or quality) adj adjusted) or (adjusted adj2 life))).ti,ab.

13. (disutility$ or (utilit$ adj1 (health or score$ or value$ or weigh$))).ti,ab.

14. (health year equivalent or hye or hyes).ti,ab.

15. (daly or qal or qald or qale or qaly or qtime$ or qwb$).ti,ab.

16. discrete choice.ti,ab.

17. (euroqol$ or euro qol$ or eq5d$ or eq 5d$).ti,ab.

18. (hui or hui1 or hui2 or hui3).ti,ab.

19. ((quality or value$) adj3 (life or survival or well$)).ti,ab.

20. (qol or hql$ or hqol$ or h qol or hr qol or hr q1 or hrql).ti,ab.

21. rosser.ti,ab.

22. sickness impact profile.ti,ab.

23. (standard gamble or time trade$ or tto or willingness to pay).ti,ab.
24. (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform thirtysix or shortform thirty six or short form thirtysix or short form thirty six).ti,ab.
25. (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sf six or shortform six or short form six).ti,ab.
26. (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or shortform twelve or short form twelve).ti,ab.
27. (sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or shortform sixteen or short form sixteen).ti,ab.
28. (sf20 or sf 20 or short form 20 or shortform 20 or sf twenty or sftwenty or shortform twenty or short form twenty).ti,ab.
29. or/11-28
30. or/4,10,29
APPENDIX 12: METHODOLOGY CHECKLIST FOR ECONOMIC STUDIES

This checklist is designed to determine whether an economic evaluation provides evidence that is useful to inform the decision-making of the GDG. It is not intended to judge the quality of the study per se or the quality of reporting. For further information about how to complete the checklist, see The Guidelines Manual [NICE, 2009e].

Study identification

*Including author, title, reference, year of publication*

Guideline topic:  

Checklist completed by:

<table>
<thead>
<tr>
<th>Section 1: Applicability (relevance to specific guideline review question(s) and the NICE reference case). This checklist should be used first to filter out irrelevant studies.</th>
<th>Yes/Partly/No/Unclear/NA</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1 Is the study population appropriate for the guideline?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.2 Are the interventions appropriate for the guideline?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.3 Is the healthcare system in which the study was conducted sufficiently similar to the current UK NHS context?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.4 Are costs measured from the NHS and personal social services (PSS) perspective?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.5 Are all direct health effects on individuals included?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.6 Are both costs and health effects discounted at an annual rate of 3.5%?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.7 Is the value of health effects expressed in terms of quality-adjusted life years (QALYs)?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.8 Are changes in health-related quality of life (HRQoL) reported directly from patients and/or carers?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.9 Is the valuation of changes in HRQoL (utilities) obtained from a representative sample of the general public?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.10 Overall judgement: Directly applicable/Partially applicable/Not applicable</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

There is no need to use section 2 of the checklist if the
study is considered ‘not applicable’.

Other comments:

<table>
<thead>
<tr>
<th>Section 2: Study limitations (the level of methodological quality) This checklist should be used once it has been decided that the study is sufficiently applicable to the context of the clinical guideline.</th>
<th>Yes/ Partly/ No/ Unclear/ NA</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1 Does the model structure adequately reflect the nature of the health condition under evaluation?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.2 Is the time horizon sufficiently long to reflect all important differences in costs and outcomes?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.3 Are all important and relevant health outcomes included?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.4 Are the estimates of baseline health outcomes from the best available source?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.5 Are the estimates of relative treatment effects from the best available source?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.6 Are all important and relevant costs included?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.7 Are the estimates of resource use from the best available source?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.8 Are the unit costs of resources from the best available source?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.9 Is an appropriate incremental analysis presented or can it be calculated from the data?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.10 Are all important parameters whose values are uncertain subjected to appropriate sensitivity analysis?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.11 Is there no potential conflict of interest?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.12 Overall assessment: Minor limitations/Potentially serious limitations/Very serious limitations</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
APPENDIX 13: RESEARCH RECOMMENDATIONS

The Guideline Development Group has made the following recommendations for research, based on its review of evidence, to improve NICE guidance and patient care in the future.

1.1 GUIDED SELF-INSTRUCTION FOR ANXIETY AND DEPRESSION IN AUTISM

What is the clinical and cost effectiveness of facilitated self-help for the treatment of mild anxiety and depressive disorders in adults with autism?

Why is this important?

Anxiety and depressive disorders are commonly coexisting disorders in people with autism and are associated with poorer health outcomes and quality of life. This may occur because of the direct impact of the anxiety or depression but also because of a negative interaction with the core symptoms of autism. There is limited access and poor uptake of such interventions by people with autism in significant part due to limited availability, but also because current systems for the delivery of facilitated self-help are not adapted for use by people with autism. In adults without autism facilitated self-help is an effective intervention for mild to moderate depression and anxiety. The development of novel methods for the delivery of facilitated self-help could make effective interventions available to a wider group of people than is currently the case.

The suggested programme of research would need to: (a) develop current methods for the delivery of self-help measures to take into account the impact of the autism and possibly include developments in the nature of the materials, the methods for their delivery and the nature, duration and extent of their facilitation; (b) test the feasibility of the novel methods in a series of pilot studies; and (c) formally evaluate the outcome (including symptoms, satisfaction and quality of life) in a large-scale randomised trial.

1.2 THE STRUCTURE AND ORGANISATION OF SPECIALIST TEAMS

What structures and organisation for specialist autism teams are associated with improvements in care for people with autism?

Why this is important
The Department of Health’s autism strategy (2010)\(^2\) proposes the introduction of a range of specialist services for people with autism; these will usually be built around specialist autism teams. However, there is little evidence to guide the establishment and development of these teams including uncertainty about the precise nature of the population to be served (all people with autism or only those who are ‘high functioning’), the composition of the team, the extent of the team’s role (for example, diagnosis and assessment only, a primarily advisory role or a substantial care coordination role), the interventions provided by the team and the team’s role and relationship with regard to non-statutory care providers. Therefore it is likely that in the near future a number of different models will be developed, which are likely to have varying degrees of success in meeting the needs of people with autism. Given the significant expansion of services, this presents an opportunity for a large-scale observational study, which should provide important information on the characteristics of teams associated with positive outcomes for people with autism in terms of access to services, effective coordination of care and outcomes for service users and their families.

\section*{1.3 AUGMENTED COMMUNICATION DEVICES FOR ADULTS WITH AUTISM}

What is the clinical and cost effectiveness of augmented communication devices for adults with autism?

\textit{Why is this important?}

Many people with autism experience very significant communication problems (for example, the absence of any spoken language, significant deficits in interpersonal skills), which have a profound effect on their ability to lead a full and rewarding life. It is probable that these problems are related to the core symptoms of autism and are likely to persist for most people given the life-long course of autism and the lack of effective interventions for these core symptoms. A number of communication devices have been developed for autism but few if any have been subjected to a proper evaluation in adults. Despite this lack of formal evaluation, individual services have made considerable investments in augmented communication devices. Research that provides high-quality evidence on the acceptability and the clinical and cost effectiveness of augmented communication devices could bring about significant improvements in the lives of adults with autism.

The suggested programme of research would need to identify current devices for which there is: (a) some evidence of benefit (for example, case series and small scale pilot studies); (b) some evidence that it meets a key communication need for people with autism (based on reviews of people’s need in this area); and (c) indication that

the device is feasible for routine use. The identified device(s) should then be formally evaluated in a large-scale randomised trial.